https://www.market-scope.com/ https://www.market-scope.com/pages/reports?page=1 https://www.market-scope.com/ophthalmic-market-trends https://www.market-scope.com/disease-models https://www.market-scope.com/ophthalmic-newsletter https://www.market-scope.com/atlases https://www.market-scope.com/pages/reports/deals?page=1 https://www.market-scope.com/pages/news https://www.market-scope.com/pages/physicians https://www.market-scope.com/pages/primary-research https://www.market-scope.com/plus https://www.market-scope.com/pages/methodology https://www.market-scope.com/pages/about https://www.market-scope.com/pages/news/9059/cencora-to-acquire-eyesouth-partners-retina-business-for-1-1-billion https://www.market-scope.com/pages/reports/561/2026-iol-market-report-global-analysis-for-2025-to-2031-march-2026 https://www.market-scope.com/careers https://www.market-scope.com/pages/privacy-policy https://www.market-scope.com/pages/reports/covid-19?page=1 https://www.market-scope.com/pages/reports/cataract?page=1 https://www.market-scope.com/pages/reports/china?page=1 https://www.market-scope.com/pages/reports/corneal?page=1 https://www.market-scope.com/pages/reports/device?page=1 https://www.market-scope.com/pages/reports/disease-prevalence?page=1 https://www.market-scope.com/pages/reports/equipment?page=1 https://www.market-scope.com/pages/reports/diagnostic?page=1 https://www.market-scope.com/pages/reports/exudative?page=1 https://www.market-scope.com/pages/reports/dry-eye?page=1 https://www.market-scope.com/pages/reports/financing?page=1 https://www.market-scope.com/pages/reports/glaucoma?page=1 https://www.market-scope.com/pages/reports/europe?page=1 https://www.market-scope.com/pages/reports/india?page=1 https://www.market-scope.com/pages/reports/instruments?page=1 https://www.market-scope.com/pages/reports/landscape?page=1 https://www.market-scope.com/pages/reports/laser?page=1 https://www.market-scope.com/pages/reports/market-opportunity?page=1 https://www.market-scope.com/pages/reports/newsletter?page=1 https://www.market-scope.com/pages/reports/overview?page=1 https://www.market-scope.com/pages/reports/patient-demographics?page=1 https://www.market-scope.com/pages/reports/phaco?page=1 https://www.market-scope.com/pages/reports/pharma?page=1 https://www.market-scope.com/pages/reports/pharmaceutical?page=1 https://www.market-scope.com/pages/reports/presbyopia?page=1 https://www.market-scope.com/pages/reports/quarterly?page=1 https://www.market-scope.com/pages/reports/quarterly-market-trends?page=1 https://www.market-scope.com/pages/reports/refractive?page=1 https://www.market-scope.com/pages/reports/retina?page=1 https://www.market-scope.com/pages/reports/surgical?page=1 https://www.market-scope.com/pages/reports/survey-data?page=1 https://www.market-scope.com/pages/reports/viscoelastics?page=1 https://www.market-scope.com/pages/reports?page=2 https://www.market-scope.com/pages/reports?page=3 https://www.market-scope.com/pages/reports?page=5 https://www.market-scope.com/pages/reports/iol?page=1 https://www.market-scope.com/pages/reports/562/ophthalmic-market-perspectives-monthly-newsletter-march-2026 https://www.market-scope.com/pages/reports/563/2025-india-ophthalmic-market-report-regional-analysis-for-2024-to-2030-march-2026 https://www.market-scope.com/pages/reports/554/2025-retinal-disease-model-february-2026 https://www.market-scope.com/pages/reports/555/2025-corneal-disease-model-february-2026 https://www.market-scope.com/pages/reports/550/2025-ophthalmic-diagnostic-equipment-survey-report-january-2026 https://www.market-scope.com/pages/reports?page=4 https://www.market-scope.com/pages/reports/552/2025-cataract-pharmaceuticals-market-report-analysis-of-united-states-and-western-europe-for-2024-to-2030-january-2026 https://www.market-scope.com/pages/reports/545/2025-dry-eye-pharmaceuticals-market-report-global-analysis-for-2024-to-2030-december-2025 https://www.market-scope.com/pages/reports/ocular-surface?page=1 https://www.market-scope.com/pages/reports/546/2025-cornea-products-market-report-global-analysis-for-2024-to-2030-december-2025 https://www.market-scope.com/pages/reports/548/2025-dry-eye-device-market-report-global-analysis-for-2024-to-2030-december-2025 https://www.market-scope.com/pages/reports/559/ophthalmic-market-trends-us-cataract-edition-q4-2025 https://www.market-scope.com/pages/reports/557/ophthalmic-market-trends-us-refractive-edition-q4-2025 https://www.market-scope.com/pages/reports/558/ophthalmic-market-trends-us-glaucoma-edition-q4-2025 https://www.market-scope.com/pages/reports/556/ophthalmic-market-trends-us-retina-edition-q4-2025 https://www.market-scope.com/pages/reports/517/2025-glaucoma-disease-model-july-2025 https://www.market-scope.com/pages/reports/514/2025-refractive-error-model-june-2025 https://www.market-scope.com/pages/reports/489/2024-corneal-disease-model-february-2025 https://www.market-scope.com/pages/reports/440/2024-united-states-cataract-atlas-featuring-the-market-scope-exclusive-medop-index-analysis-april-2024 https://www.market-scope.com/pages/reports/439/2024-united-states-refractive-atlas-featuring-the-market-scope-exclusive-medop-index-analysis-march-2024 https://www.market-scope.com/pages/reports/388/2023-united-states-retina-atlas-featuring-the-market-scope-exclusive-medop-index-analysis-june-2023 https://www.market-scope.com/pages/reports/317/2022-united-states-glaucoma-atlas https://www.market-scope.com/pages/reports/mergers?page=1 https://www.market-scope.com/pages/reports/acquisitions?page=1 https://www.market-scope.com/pages/reports/funding?page=1 https://www.market-scope.com/pages/reports/551/ophthalmic-deals-report-q4-2025 https://www.market-scope.com/pages/news/breaking https://www.market-scope.com/pages/news/cell-therapy https://www.market-scope.com/pages/news/clinical-trial https://www.market-scope.com/pages/news/cataract https://www.market-scope.com/pages/news/corneal https://www.market-scope.com/pages/news/china https://www.market-scope.com/pages/news/diagnostic https://www.market-scope.com/pages/news/device https://www.market-scope.com/pages/news/digital https://www.market-scope.com/pages/news/deals https://www.market-scope.com/pages/news/dry-eye https://www.market-scope.com/pages/news/europe https://www.market-scope.com/pages/news/gene-therapy https://www.market-scope.com/pages/news/equipment https://www.market-scope.com/pages/news/glaucoma https://www.market-scope.com/pages/news/india https://www.market-scope.com/pages/news/instruments https://www.market-scope.com/pages/news/industry https://www.market-scope.com/pages/news/low-vision https://www.market-scope.com/pages/news/laser https://www.market-scope.com/pages/news/ocular-cancer https://www.market-scope.com/pages/news/newsletter https://www.market-scope.com/pages/news/optometry https://www.market-scope.com/pages/news/meeting https://www.market-scope.com/pages/news/presbyopia https://www.market-scope.com/pages/news/press-release https://www.market-scope.com/pages/news/pharma https://www.market-scope.com/pages/news/refractive https://www.market-scope.com/pages/news/regulation https://www.market-scope.com/pages/news/study https://www.market-scope.com/pages/news/survey https://www.market-scope.com/pages/news/retina https://www.market-scope.com/pages/news/transplant https://www.market-scope.com/pages/news/surgical https://www.market-scope.com/pages/news/thyroid-eye-disease https://www.market-scope.com/pages/news/uveitis https://www.market-scope.com/pages/news/9058/regulators-in-china-approve-lotilaner-drops-triggering-15-million-payment-to-tarsus https://www.market-scope.com/pages/news/9057/2025-ophthalmic-revenue-roundup-for-iridex-and-lenz https://www.market-scope.com/pages/news/9040/2026-apao-meeting-in-hong-kong-attracts-surgeons-from-111-countries https://www.market-scope.com/pages/news/9056/jandj-continues-to-reduce-jlabs-footprint-with-exit-from-new-york https://www.market-scope.com/pages/news/9055/zeiss-expands-clinical-ophthalmic-and-optometric-device-portfolio-in-canada https://www.market-scope.com/pages/news/9054/innovent-reports-positive-phase-iii-results-for-extended-dosing-retinal-candidate https://www.market-scope.com/pages/news/9053/lineage-launches-new-cell-therapy-program-in-corneal-endothelial-disease https://www.market-scope.com/pages/news/9052/us-fda-grants-orphan-drug-status-to-sumitomo-s-rp-cell-therapy-candidate https://www.market-scope.com/pages/news/9039/2026-ags-meeting-showcases-products-designed-for-earlier-intervention https://www.market-scope.com/pages/news/9032/ophthalmic-company-revenue-down-1-8-percent-in-q4-2025-seven-firms-see-declines https://www.market-scope.com/pages/news/9027/ophthalmologists-report-2-1-percent-decrease-in-q4-2025-procedure-volume https://www.market-scope.com/pages/news/9045/alcon-lensar-scrap-acquisition-deal-in-face-of-ftc-opposition-1 https://www.market-scope.com/pages/news/9035/premium-iols-move-mainstream-as-revenue-growth-accelerates-globally https://www.market-scope.com/pages/news/9043/jandj-vision-gains-us-fda-approval-for-tecnis-puresee-edof-iol-1 https://www.market-scope.com/pages/news/9046/meet-with-market-scope-at-the-ascrs-meeting https://www.market-scope.com/pages/news/9051/pdufa-dates-for-ophthalmic-drug-candidates-march-2026 https://www.market-scope.com/pages/news/9050/us-fda-rejects-chiesi-s-idebenone-for-lhon-asks-for-more-clinical-data-1 https://www.market-scope.com/pages/news/9049/select-us-fda-approvals-and-clearances-in-february-2026 https://www.market-scope.com/pages/news/9044/oertli-launches-os-4-up-dual-function-cataract-vitrectomy-system-in-europe https://www.market-scope.com/pages/news/9047/rayner-expands-us-headquarters-in-memphis-amid-milestone-successes-1 https://www.market-scope.com/pages/news/9048/us-fda-again-rejects-aldeyra-s-reproxalap-for-dry-eye-citing-trial-failures-1 https://www.market-scope.com/pages/news/9041/science-corp-leads-latest-fundraising-with-230-million-in-series-c https://www.market-scope.com/pages/news-archive https://www.market-scope.com/pages/news/9042/children-s-hospital-los-angeles-pioneers-aqueous-biopsy-test-for-ocular-cancer-1 https://www.market-scope.com/pages/about/dave-harmon https://www.market-scope.com/pages/about/bill-freeman https://www.market-scope.com/pages/about/tony-ingenito https://www.market-scope.com/pages/about/kristen-harmon-ingenito https://www.market-scope.com/pages/about/joan-mckenna https://www.market-scope.com/pages/about/nathan-jones https://www.market-scope.com/pages/about/chelsea-jones https://www.market-scope.com/pages/about/peter-downs https://www.market-scope.com/pages/about/ethan-wallace https://www.market-scope.com/pages/about/matthew-douty https://www.market-scope.com/pages/about/krista-davidson https://www.market-scope.com/pages/about/jennie-crabbe https://www.market-scope.com/pages/about/sharon-gotter https://www.market-scope.com/pages/about/katherine-brouillet https://www.market-scope.com/pages/reports https://www.market-scope.com/pages/about/tanner-ray https://www.market-scope.com/pages/reports/518/2025-cataract-surgical-equipment-market-report-global-analysis-for-2024-to-2030-july-2025 https://www.market-scope.com/pages/data-policy https://www.market-scope.com/pages/reports/531/2025-premium-cataract-surgery-market-report-analysis-of-the-top-13-countries-for-2024-to-2030-october-2025 https://www.market-scope.com/pages/testimonials https://www.market-scope.com/pages/reports/173/covid-19-united-states-surgeon-survey-report-march-2020 https://www.market-scope.com/pages/reports/premium?page=1 https://www.market-scope.com/pages/reports/flacs?page=1 https://www.market-scope.com/pages/reports/cataract?page=2 https://www.market-scope.com/pages/reports/543/2025-single-use-ophthalmic-surgical-products-market-report-global-analysis-for-2024-to-2030-november-2025 https://www.market-scope.com/pages/reports/disposable?page=1 https://www.market-scope.com/pages/reports/single-use?page=1 https://www.market-scope.com/pages/reports/515/2025-china-ophthalmic-market-report-regional-analysis-for-2024-to-2030-july-2025 https://www.market-scope.com/pages/reports/510/2025-united-states-cataract-surgeon-survey-report-june-2025 https://www.market-scope.com/pages/reports/509/2025-european-five-ophthalmic-market-report-regional-analysis-for-2024-to-2030-may-2025 https://www.market-scope.com/pages/reports/520/2025-glaucoma-surgical-device-market-report-global-analysis-for-2024-to-2030-august-2025 https://www.market-scope.com/pages/reports/499/2025-retinal-device-market-report-global-analysis-for-2024-to-2030-march-2025 https://www.market-scope.com/pages/reports/refractive-error?page=1 https://www.market-scope.com/pages/reports/527/2025-ophthalmic-diagnostic-equipment-market-report-global-analysis-for-2024-to-2030-september-2025 https://www.market-scope.com/pages/reports/fundus?page=1 https://www.market-scope.com/pages/reports/microscopes?page=1 https://www.market-scope.com/pages/reports/oct?page=1 https://www.market-scope.com/pages/reports/544/2025-ophthalmic-or-microscopes-market-report-global-analysis-for-2024-to-2030-november-2025 https://www.market-scope.com/pages/reports/547/2025-optical-coherence-tomography-market-report-global-analysis-for-2024-to-2030-november-2025 https://www.market-scope.com/pages/reports/542/2025-fundus-imaging-market-report-global-analysis-for-2024-to-2030-october-2025 https://www.market-scope.com/pages/reports/530/2025-exudative-retinal-disease-pharmaceuticals-market-report-october-2025 https://www.market-scope.com/pages/reports/wet-amd?page=1 https://www.market-scope.com/pages/reports/541/2025-ocular-surface-disease-survey-report-october-2025 https://www.market-scope.com/pages/reports/500/2024-ophthalmic-landscape-market-report-global-analysis-for-2023-to-2029-april-2025 https://www.market-scope.com/pages/reports/glaucoma?page=2 https://www.market-scope.com/pages/reports/501/2025-glaucoma-pharmaceuticals-market-report-global-analysis-for-2024-to-2030-april-2025 https://www.market-scope.com/pages/reports/atlas?page=1 https://www.market-scope.com/pages/reports/316/2022-india-ophthalmic-market-report https://www.market-scope.com/pages/reports/reusable?page=1 https://www.market-scope.com/pages/reports/525/2025-ophthalmic-surgical-instruments-market-report-global-analysis-for-2024-to-2030-august-2025 https://www.market-scope.com/pages/reports/496/2024-ophthalmic-laser-market-report-global-analysis-for-2023-to-2029-march-2025 https://www.market-scope.com/pages/reports/536/2025-nonexudative-retinal-disease-pharmaceuticals-market-report-global-analysis-for-2024-to-2030-october-2025 https://www.market-scope.com/pages/reports/381/2023-us-and-western-europe-cataract-pharmaceuticals-market-report-may-2023 https://www.market-scope.com/pages/reports/511/2025-presbyopia-correction-survey-report-june-2025 https://www.market-scope.com/pages/reports/512/2025-presbyopia-correction-market-report-global-analysis-for-2024-to-2030-june-2025 https://www.market-scope.com/pages/reports/myopia?page=1 https://www.market-scope.com/pages/reports/528/2025-refractive-surgery-market-report-global-analysis-for-2024-to-2030-september-2025 https://www.market-scope.com/pages/reports/retina?page=2 https://www.market-scope.com/pages/reports/survey-data?page=2 https://www.market-scope.com/pages/reports/549/2025-myopia-management-survey-report-december-2025 https://www.market-scope.com/pages/reports/325/2022-annual-sponsored-us-cataract-surgeon-survey-report-may-2022 https://www.market-scope.com/files/products/brochures/531/2025%20PCS%20Report%20Brochure.pdf https://www.market-scope.com/files/products/brochures/536/2025%20Nonexudative%20Retina%20Pharma%20Report%20Brochure.pdf https://www.market-scope.com/files/products/brochures/541/2025%20OSD%20Survey%20Info.pdf https://www.market-scope.com/files/products/brochures/542/2025%20Fundus%20Imaging%20Report%20Brochure.pdf https://www.market-scope.com/files/products/brochures/527/2025%20Diagnostic%20Equipment%20Report%20Brochure.pdf https://www.market-scope.com/files/products/brochures/528/2025%20Refractive%20Market%20Report%20Brochure.pdf https://www.market-scope.com/files/products/brochures/520/2025%20Glaucoma%20Device%20Report%20Brochure.pdf https://www.market-scope.com/files/products/brochures/525/2025%20Surgical%20Instruments%20Report%20Brochure.pdf https://www.market-scope.com/files/products/brochures/515/2025%20China%20Ophthalmic%20Market%20Report%20Brochure.pdf https://www.market-scope.com/files/products/brochures/517/Disease%20Models%20Brochure.pdf https://www.market-scope.com/pages/news/7134/2026-ophthalmic-meetings-calendar https://www.market-scope.com/pages/news/9025/alcon-lensar-scrap-acquisition-deal-in-face-of-ftc-opposition https://www.market-scope.com/pages/news/9024/us-fda-again-rejects-aldeyra-s-reproxalap-for-dry-eye-citing-trial-failures https://www.market-scope.com/pages/news/9023/glaukos-launches-epioxa-epi-on-crosslinking-therapy-for-keratoconus https://www.market-scope.com/pages/news/9022/new-law-in-kansas-expands-ods-scope-to-include-laser https://www.market-scope.com/pages/news/9021/formycon-settlement-clears-way-for-eylea-biosimilar-in-europe-other-markets https://www.market-scope.com/pages/news/9020/super-vision-gains-china-approval-of-i-nys-implant-for-congenital-nystagmus https://www.market-scope.com/pages/news/9019/amydis-wins-2-5-million-nih-grant-to-advance-retinal-tracer-for-als https://www.market-scope.com/pages/news/9018/heru-s-new-pretestpro-for-vr-headset-runs-four-visual-exams-in-under-2-minutes https://www.market-scope.com/pages/news/9017/jandj-vision-gains-us-fda-approval-for-tecnis-puresee-edof-iol https://www.market-scope.com/pages/news/9016/2025-ophthalmic-revenue-roundup-for-staar-surgical-and-sight-sciences https://www.market-scope.com/pages/news/9014/us-fda-rejects-chiesi-s-idebenone-for-lhon-asks-for-more-clinical-data https://www.market-scope.com/pages/news/9015/lenz-submits-marketing-application-for-vizz-presbyopia-drop-in-europe https://www.market-scope.com/pages/news/9013/aravind-eye-surgeons-named-as-2026-chang-crandall-humanitarian-award-recipients https://www.market-scope.com/pages/news/9011/glaucoma-research-foundation-awards-record-3-06-million-in-annual-research-grants https://www.market-scope.com/pages/news/9010/cassini-gains-mdr-approval-for-surgical-guidance-system-in-the-eu https://www.market-scope.com/pages/news/9012/rayner-expands-us-headquarters-in-memphis-amid-milestone-successes https://www.market-scope.com/pages/news/9009/qlaris-bio-appoints-fred-guerard-pharmd-as-president-and-ceo https://www.market-scope.com/pages/news/9008/virtual-field-maker-of-vr-perimetry-headsets-rebrands-as-carrot https://www.market-scope.com/pages/news/9007/oertli-launches-os-4-up-dual-function-cataract-vitrectomy-system https://www.market-scope.com/pages/news/9006/ophthalmic-quarterly-and-2025-revenue-for-carl-zeiss-meditec-harrow-rxsight-ani-and-xbrane https://www.market-scope.com/pages/news/9005/rayner-acquires-distribution-rights-to-anikavisc-ovd-in-us https://www.market-scope.com/pages/news/9004/us-fda-gives-green-light-to-phase-iii-trial-of-harrow-s-triesence-for-post-op-inflammation-and-pain https://www.market-scope.com/pages/news/9003/alcon-lensar-deal-now-expected-to-close-in-first-half-of-2026 https://www.market-scope.com/pages/news/9002/us-fda-gives-green-light-to-phase-i-ii-trial-of-sanaregen-s-retinal-cell-therapy-candidate https://www.market-scope.com/pages/news/9000/cirrus-expands-to-singapore-unveils-ga-cell-therapy-candidate https://www.market-scope.com/pages/news/8999/axol-bioscience-acquires-ophthalmology-business-from-newcells-biotech https://www.market-scope.com/pages/news/9001/sandoz-reports-eu-approval-for-ranibizumab-biosimilar-branded-ranluspec https://www.market-scope.com/pages/news/8998/eyemd-electronic-health-records-platform-rebrands-as-optivate https://www.market-scope.com/pages/news/8997/us-fda-accepts-snda-for-opus-presbyopia-candidate-sets-pdufa-date-of-oct-17-2026 https://www.market-scope.com/pages/news/8996/2025-ophthalmic-revenue-roundup-for-alcon-apellis-tarsus-and-immunocore https://www.market-scope.com/pages/news/8995/children-s-hospital-los-angeles-pioneers-aqueous-biopsy-test-for-ocular-cancer https://www.market-scope.com/pages/news/8993/helpmesee-launches-simulation-based-msics-training-centers-in-ghana-nigeria https://www.market-scope.com/pages/news/8992/formosa-licenses-clobetasol-drops-to-arrotex-for-australia-new-zealand https://www.market-scope.com/pages/news/8994/outlook-grants-mediconsult-rights-to-market-lytenava-in-switzerland https://www.market-scope.com/pages/news/8991/us-fda-gives-green-light-to-phase-ii-iii-trial-of-nexeos-bio-s-vernal-keratoconjunctivitis-candidate https://www.market-scope.com/pages/news/8990/us-fda-gives-green-light-to-phase-ii-trial-of-cloudbreak-s-presbyopia-drop-candidate https://www.market-scope.com/pages/news/8961/us-fda-will-drop-two-study-requirement-for-new-drug-approvals https://www.market-scope.com/pages/news/8967/2025-ophthalmic-revenue-roundup-for-bausch-and-lomb-and-glaukos https://www.market-scope.com/pages/news/8964/us-fda-expands-indication-for-staar-s-evo-icl-to-patients-up-to-age-60 https://www.market-scope.com/pages/news/8962/ocular-therapeutix-reports-positive-results-for-axpaxli-vs-eylea-in-phase-iii-wet-amd-trial https://www.market-scope.com/pages/news/8966/aoa-sounds-alert-on-eyebot-vision-kiosks-calls-for-greater-oversight https://www.market-scope.com/pages/news/8963/eye-pcr-gains-ce-marking-for-fixoflex-endocapsular-device https://www.market-scope.com/pages/news/8968/private-equity-firm-sells-maker-of-reteval-erg-device-to-ametek https://www.market-scope.com/pages/news/8965/okyo-pharma-appoints-flavio-mantelli-md-phd-as-chief-medical-officerokyo-pharma-appoints-flavio-mantelli-md-phd-as-chief-medical-officer https://www.market-scope.com/pages/news/8956/2025-and-quarterly-ophthalmic-revenue-roundup-for-amgen-santen-hoya-lumibird-and-ocular-therapeutix https://www.market-scope.com/pages/news/8957/new-us-law-institutes-major-pharmacy-benefit-manager-reforms-in-2029 https://www.market-scope.com/pages/news/8958/belgian-company-invests-500-million-euros-for-45-percent-stake-in-rayner https://www.market-scope.com/pages/news/8959/samsung-bioepis-deals-with-regeneron-clear-way-for-eylea-biosimilar-in-us-other-markets https://www.market-scope.com/pages/news/8953/nordic-pharma-launches-lacrifill-canalicular-gel-for-dry-eye-in-europe https://www.market-scope.com/pages/news/8960/american-college-of-eye-technicians-offers-fast-track-virtual-training-program https://www.market-scope.com/pages/news/8954/arctic-vision-to-acquire-mdco-technology-s-ophthalmic-device-business https://www.market-scope.com/pages/news/8955/meiragtx-licenses-zipbio-s-protein-therapeutic-technology-for-ga https://www.market-scope.com/pages/news/8950/sandoz-launches-aflibercept-biosimilar-enzeevu-in-canada https://www.market-scope.com/pages/news/8951/alvotech-s-deal-with-regeneron-bayer-clears-way-for-eylea-biosimilar-in-multiple-markets https://www.market-scope.com/pages/news/8949/staar-names-warren-foust-and-deborah-andrews-as-interim-co-ceos-amid-search-for-permanent-leader https://www.market-scope.com/pages/news/8948/harrow-ends-compounded-product-sales-in-california-plans-to-sell-all-products-under-harrow-label https://www.market-scope.com/pages/news/8952/quarterly-and-2025-ophthalmic-revenue-roundup-for-roche-regeneron-abbvie-novartis-and-astellas https://www.market-scope.com/pages/news/8947/us-fda-gives-green-light-to-trial-of-life-bio-s-cell-rejuvenation-candidate-in-optic-neuropathies https://www.market-scope.com/pages/news/8946/santen-gains-approval-in-japan-for-rvl-s-blepharoptosis-drops-under-name-upneeq-mini https://www.market-scope.com/pages/news/8945/opus-launches-trial-in-abu-dhabi-for-rp-gene-therapy-candidate https://www.market-scope.com/pages/news/8944/merged-southeastern-us-eye-banks-will-be-known-as-precision-ocular-network https://www.market-scope.com/pages/news/8943/us-fda-grants-orphan-drug-status-to-bluerock-s-rp-cell-therapy-candidate https://www.market-scope.com/pages/news/8942/us-fda-grants-fast-track-status-to-drug-farm-s-rosah-candidate https://www.market-scope.com/pages/news/8939/us-fda-approves-re-administration-of-glaukos-idose-tr https://www.market-scope.com/pages/news/8938/us-fda-approves-tenpoint-s-yuvezzi-drops-for-presbyopia https://www.market-scope.com/pages/news/8941/orbis-international-appoints-kathleen-sherwin-mba-as-president-and-ceo https://www.market-scope.com/pages/news/8940/eu-india-free-trade-agreement-to-phase-in-lower-pharma-and-device-tariffs https://www.market-scope.com/pages/news/8937/us-fda-rolls-out-precheck-program-to-speed-approval-of-drug-manufacturing-plants https://www.market-scope.com/pages/news/8936/nidek-launches-the-phantom-open-field-refraction-system https://www.market-scope.com/pages/news/8934/us-fda-authorizes-compassionate-use-of-urcosimod-for-neuropathic-corneal-pain https://www.market-scope.com/pages/news/8933/emmecell-appoints-ramin-valian-as-chief-executive-officer https://www.market-scope.com/pages/news/8935/us-fda-gives-green-light-to-phase-ii-trial-of-novaliq-s-topical-uveitis-candidate https://www.market-scope.com/pages/news/8930/rayner-launches-sophi-phaco-machine-in-the-us https://www.market-scope.com/pages/news/8929/eylea-8-mg-gains-eu-approval-to-treat-macular-edema-following-rvo https://www.market-scope.com/pages/news/8931/jandj-vision-reports-2025-surgical-vision-revenue-of-1-6-billion https://www.market-scope.com/pages/news/8928/bioage-enters-ophthalmology-with-oral-nlrp3-inhibitor-candidate-for-dme https://www.market-scope.com/pages/news/8927/biotissue-sells-non-ophthalmic-surgical-and-wound-care-business-to-biostem https://www.market-scope.com/pages/news/8926/nanoscope-s-mco-010-gains-sakigake-pioneer-and-orphan-drug-status-in-japan https://www.market-scope.com/pages/news/8925/bvi-medical-appoints-jim-hollingshead-phd-as-president-and-ceo https://www.market-scope.com/pages/news/8896/staar-agrees-to-leadership-changes-following-failed-acquisition-attempt https://www.market-scope.com/pages/news/8894/topcon-healthcare-partners-with-remonihealth-for-remote-eye-screening https://www.market-scope.com/pages/news/8893/us-fda-gives-green-light-to-trial-of-allotex-tissue-implant-for-presbyopia https://www.market-scope.com/pages/news/8895/formosa-licenses-clobetasol-drops-to-samil-for-south-korea https://www.market-scope.com/pages/news/8892/ikarovec-signs-option-to-license-ivt-capsid-technology-for-use-with-amd-gene-therapy https://www.market-scope.com/pages/news/8891/bio-usawa-gains-approval-for-lucentis-biosimilar-in-rwanda-ghana https://www.market-scope.com/pages/news/8890/gensight-gains-compassionate-use-authorization-for-lumevoq-in-france-and-israel https://www.market-scope.com/pages/news/8889/nanodropper-now-mu-medical-plans-combination-with-bedo-and-viseon https://www.market-scope.com/pages/news/8888/us-fda-grants-fast-track-status-to-complement-s-ga-gene-therapy-candidate https://www.market-scope.com/pages/news/8887/us-fda-gives-green-light-to-trial-of-genedit-bio-s-corneal-gene-editing-candidate https://www.market-scope.com/pages/news/8886/vivavision-needs-single-us-phase-iii-trial-for-uveitis-nda-fda-says https://www.market-scope.com/pages/news/8880/staar-surgical-calls-off-alcon-acquisition-deal-after-failed-shareholder-vote https://www.market-scope.com/pages/news/8885/christopher-j-rapuano-md-to-use-aao-presidency-to-focus-on-emergency-eye-care https://www.market-scope.com/pages/news/8884/nei-study-shows-gene-variants-don-t-always-lead-to-irds https://www.market-scope.com/pages/news/8883/okyo-pharma-appoints-industry-veteran-robert-j-dempsey-as-ceo https://www.market-scope.com/pages/news/8881/us-fda-grants-breakthrough-status-to-oculis-privosegtor-for-optic-neuritis https://www.market-scope.com/pages/news/8879/us-fda-rejects-outlook-s-lytenava-for-a-third-time-citing-lack-of-efficacy-evidence https://www.market-scope.com/pages/news/8882/lenz-signs-deal-with-lunatus-for-marketing-of-vizz-in-middle-east https://www.market-scope.com/pages/news/8878/us-fda-approves-ranibizumab-lucentis-biosimilar-from-bioeq-formycon https://www.market-scope.com/pages/news/8877/us-fda-accepts-viridian-s-ted-candidate-for-priority-review-sets-pdufa-date-of-june-30-2026 https://www.market-scope.com/pages/news/8876/alvotech-teva-reach-deal-with-regeneron-to-bring-eylea-biosimilar-to-us-market-no-later-than-h2-2026 https://www.market-scope.com/pages/news/8875/cms-issues-billing-codes-for-cellution-s-allograft-balance-s-pressure-goggles https://www.market-scope.com/pages/news/8874/us-fda-gives-green-light-to-trial-of-viatris-gene-therapy-candidate-for-nk https://www.market-scope.com/pages/news/8873/virtual-retina-could-help-unlock-new-treatments-for-vision-loss-researchers-say https://www.market-scope.com/pages/news/8872/usc-roski-eye-takes-part-in-phase-iib-trial-of-rpe-patch-candidate-for-ga https://www.market-scope.com/pages/news/8871/meibum-scientific-appoints-ryan-s-bleeks-as-interim-ceo https://www.market-scope.com/pages/news/8870/evoq-launches-twilight-dark-adaptometer-in-us https://www.market-scope.com/pages/news/8869/formycon-klinge-license-eylea-biosimilar-to-ntc-for-italy https://www.market-scope.com/pages/news/8868/essilorluxottica-acquires-signify-eye-centers-in-belgium https://www.market-scope.com/pages/news/8867/argenx-pulls-plug-on-thyroid-eye-disease-program-on-recommendation-of-data-monitors https://www.market-scope.com/pages/news/8866/health-canada-approves-celltrion-s-aflibercept-biosimilar-branded-eydenzelt https://www.market-scope.com/pages/news/8864/mit-research-offers-new-treatment-approach-for-amblyopia-1 https://www.market-scope.com/pages/news/8863/amneal-gains-us-fda-approval-for-generic-version-of-restasis-for-dry-eye https://www.market-scope.com/pages/news/8865/finland-researchers-study-heat-s-role-in-slowing-progression-of-dry-amd-1 https://www.market-scope.com/pages/news/8862/alembic-gains-us-fda-approval-for-generic-of-bausch-and-lomb-s-zylet https://www.market-scope.com/pages/news/8861/kiora-joins-rare-x-consortium-promoting-collaboration-on-rare-ocular-disorders https://www.market-scope.com/pages/news/8860/alcon-exercises-right-to-again-delay-staar-shareholders-vote-on-deal https://www.market-scope.com/pages/news/8859/ocular-takes-cue-from-us-fda-will-submit-nda-for-axpaxli-after-single-phase-iii-trial https://www.market-scope.com/pages/news/8858/carl-zeiss-meditec-reports-annual-ophthalmic-revenue-of-2-billion https://www.market-scope.com/pages/news/8857/us-fda-extends-action-date-on-aldeyra-s-reproxalap-to-march-2026 https://www.market-scope.com/pages/news/8856/ntc-acquires-ophthalmology-business-of-pharmathen https://www.market-scope.com/pages/news/8855/french-regulators-give-green-light-to-dose-ranging-study-of-gensight-s-lumevoq https://www.market-scope.com/pages/news/8854/prefilled-syringe-of-byooviz-gains-positive-chmp-opinion https://www.market-scope.com/pages/news/8828/alcon-raises-bid-for-staar-surgical-large-shareholders-continue-to-oppose-deal https://www.market-scope.com/pages/news/8827/cms-finalizes-2-6-percent-increase-for-ascs-hopds-in-2026 https://www.market-scope.com/pages/news/8826/us-fda-gives-green-light-to-trial-of-eyeyon-s-endoart-artificial-corneal-implant https://www.market-scope.com/pages/news/8825/lenz-partner-lotus-pharmaceutical-submits-nda-in-korea-for-vizz-presbyopia-drop https://www.market-scope.com/pages/news/8824/santen-to-market-bayer-s-authorized-eylea-biosimilar-in-japan-after-drug-gains-coverage https://www.market-scope.com/pages/news/8823/us-fda-gives-green-light-to-trial-of-zhongmou-s-optogenetic-therapy-for-rp https://www.market-scope.com/pages/news/8822/alkeus-appoints-retina-specialist-carlos-quezada-ruiz-md-as-chief-medical-officer https://www.market-scope.com/pages/news/8820/bausch-and-lomb-outlines-growth-plans-driven-by-deep-pipeline https://www.market-scope.com/pages/news/8819/iolyx-licenses-autoimmune-dry-eye-candidate-to-thea-in-deal-worth-up-to-280-million https://www.market-scope.com/pages/news/8821/kriya-appoints-greg-di-russo-md-as-chief-medical-officer https://www.market-scope.com/pages/news/8818/formosa-licenses-clobetasol-drops-to-rxilient-for-countries-in-southeast-asia https://www.market-scope.com/pages/news/8817/cder-chief-pazdur-retiring-from-us-fda-makary-names-hoeg-as-replacement https://www.market-scope.com/pages/news/8816/clearside-to-pursue-strategic-sale-through-chapter-11-process https://www.market-scope.com/pages/news/8814/rvl-pharmaceuticals-maker-of-upneeq-appoints-lori-deo-as-ceo https://www.market-scope.com/pages/news/8815/ocuvex-resubmits-nda-to-us-fda-for-once-daily-brimonidine-drop https://www.market-scope.com/pages/news/8812/bascom-palmer-eye-institute-opens-location-in-abu-dhabi https://www.market-scope.com/pages/news/8813/visara-appoints-cadmus-rich-md-mba-as-chief-medical-officer https://www.market-scope.com/pages/news/8810/cure-blindness-project-s-2025-holiday-catalog-encourages-shoppers-to-give-gift-of-sight https://www.market-scope.com/pages/news/8809/cartwheel-to-license-clearsight-s-otc-pink-eye-treatment https://www.market-scope.com/pages/news/8808/coave-unveils-lead-gene-therapy-program-for-retinal-vascular-diseases https://www.market-scope.com/pages/news/8811/assistance-fund-charity-launches-aid-program-for-mactel-treatment https://www.market-scope.com/pages/news/8807/curative-biotech-seeks-strategic-partner-to-advance-metformin-eye-drops-for-amd https://www.market-scope.com/pages/news/8805/precise-bio-treats-first-patient-with-3d-bioprinted-corneal-implant https://www.market-scope.com/pages/news/8804/topcon-gains-us-510-k-clearance-for-omnia-4-in-1-diagnostic-device https://www.market-scope.com/pages/news/8806/xbrane-plans-to-resubmit-bla-to-us-fda-in-march-2026-for-lucentis-biosimilar https://www.market-scope.com/pages/news/8802/us-fda-approves-eylea-hd-for-rvo-plus-monthly-dosing-in-all-approved-indications https://www.market-scope.com/pages/news/8801/cellution-launches-amnioplast-allografts-in-us-for-ocular-surface-repair https://www.market-scope.com/pages/news/8803/ior-partners-rolls-out-md-od-office-based-collaboration-model https://www.market-scope.com/pages/news/8800/new-brain-stimulation-approach-improves-vision-recovery-after-stroke https://www.market-scope.com/pages/news/8774/lilly-meiragtx-sign-ophthalmic-gene-therapy-deal-worth-up-to-475-million https://www.market-scope.com/pages/news/8799/two-leading-eye-banks-based-in-southeastern-us-announce-merger https://www.market-scope.com/pages/news/8771/staar-solicits-new-bids-under-amended-deal-with-alcon-moves-shareholder-vote-to-dec-19 https://www.market-scope.com/pages/news/8773/q3-2025-ophthalmic-revenue-roundup-for-alcon-santen-immunocore-staar-harrow-and-five-others https://www.market-scope.com/pages/news/8772/sydnexis-gains-uk-approval-for-low-dose-atropine-drops-in-pediatric-myopia https://www.market-scope.com/pages/news/8768/kwangdong-submits-nda-in-south-korea-for-tenpoint-s-presbyopia-drop https://www.market-scope.com/pages/news/8770/richard-pazdur-md-to-lead-us-fda-s-center-for-drug-evaluation-and-research https://www.market-scope.com/pages/news/8767/mallinckrodt-spins-off-generics-business-rebrands-as-keenova https://www.market-scope.com/pages/news/8769/uk-high-court-ruling-paves-way-for-launch-of-alvotech-s-aflibercept-biosimilar https://www.market-scope.com/pages/news/8762/viridian-submits-bla-to-us-fda-for-veligrotug-in-thyroid-eye-disease https://www.market-scope.com/pages/news/8765/cms-changes-to-final-2026-physician-fee-schedule-include-two-significant-cuts https://www.market-scope.com/pages/news/8763/4dmt-licenses-retinal-gene-therapy-candidate-to-otsuka-for-asia-pacific https://www.market-scope.com/pages/news/8766/polyactiva-raresight-to-collaborate-on-rare-pediatric-retinal-diseases https://www.market-scope.com/pages/news/8760/uk-accepts-conditional-marketing-application-for-belite-bio-s-tinlarebant-in-stargardt https://www.market-scope.com/pages/news/8761/samsung-bioepis-to-commercialize-byooviz-in-europe-starting-in-january-2026 https://www.market-scope.com/pages/news/8764/q3-2025-ophthalmic-revenue-roundup-for-amgen-abbvie-hoya-glaukos-apellis-astellas-and-four-others https://www.market-scope.com/pages/news/8758/outlook-resubmits-bla-to-us-fda-for-ophthalmic-bevacizumab-lytenava-1 https://www.market-scope.com/pages/news/8757/visara-licenses-retinal-candidate-to-everest-for-greater-china-other-asian-countries https://www.market-scope.com/pages/news/8759/fda-clears-way-for-us-patient-to-receive-gensight-s-lumevoq-for-lhon https://www.market-scope.com/pages/news/8756/roche-reports-mixed-phase-iii-data-for-vamikibart-in-uveitic-macular-edema https://www.market-scope.com/pages/news/8755/us-fda-rejects-sydnexis-atropine-drop-for-pediatric-myopia https://www.market-scope.com/pages/news/8752/staar-moves-shareholder-vote-on-alcon-acquisition-to-dec-3 https://www.market-scope.com/pages/news/8754/lilly-to-acquire-adverum-in-deal-worth-up-to-262-million https://www.market-scope.com/pages/news/8751/us-fda-again-rejects-xbrane-s-ranibizumab-biosimilar-candidate https://www.market-scope.com/pages/news/8750/us-fda-rejects-eylea-hd-prefilled-syringe-over-inspection-at-catalent-site https://www.market-scope.com/pages/news/8753/q3-2025-ophthalmic-revenue-roundup-for-bausch-and-lomb-roche-regeneron-novartis https://www.market-scope.com/pages/news/8749/china-medical-system-acquires-rights-in-china-to-novartis-beovu-and-lucentis https://www.market-scope.com/pages/news/8747/viatris-locus-biosciences-to-collaborate-on-ophthalmic-antibacterial-therapies https://www.market-scope.com/pages/news/8748/amsurg-acquires-asc-in-south-carolina-expanding-footprint-in-state https://www.market-scope.com/pages/news/8743/us-fda-approves-glaukos-epioxa-epi-on-crosslinking-therapy-for-keratoconus-1 https://www.market-scope.com/pages/news/8746/veo-ophthalmics-launches-perivision-s-visionone-vr-visual-field-platform-in-us https://www.market-scope.com/pages/news/8745/alcon-staar-deal-up-in-the-air-as-shareholder-vote-is-delayed-1 https://www.market-scope.com/pages/news/8740/santen-acquires-rights-in-south-korea-to-novartis-beovu-and-lucentis https://www.market-scope.com/pages/news/8742/jandj-vision-surgical-posts-q3-2025-revenue-of-383-million https://www.market-scope.com/pages/news/8739/aviadobio-signs-option-to-license-ugenex-optogenetics-gene-therapy-candidate https://www.market-scope.com/pages/news/8741/topcon-healthcare-to-acquire-ai-screening-company-toku https://www.market-scope.com/pages/news/8738/us-fda-selects-abeona-s-xlrs-candidate-for-rare-disease-endpoint-program https://www.market-scope.com/pages/news/8736/us-fda-grants-orphan-drug-status-to-aavantgarde-s-stargardt-candidate https://www.market-scope.com/pages/news/8737/us-fda-grants-breakthrough-status-to-nacuity-s-oral-candidate-for-rp https://www.market-scope.com/pages/news/8986/bioage-leads-latest-ophthalmic-fundraising-with-115-million-offering https://www.market-scope.com/pages/news/8722/ocular-tx-leads-latest-ophthalmic-fundraising-with-475-million-offering https://www.market-scope.com/pages/news/8735/versea-ophthalmics-launches-as-independent-company-named-defeye https://www.market-scope.com/pages/news/8660/kriya-leads-latest-ophthalmic-fundraising-with-320-million-in-series-d https://www.market-scope.com/pages/news/8663/clinical-trial-updates-for-ophthalmic-candidates-september-2025 https://www.market-scope.com/pages/news/8651/emerging-companies-pursuing-ophthalmic-indications-september-2025 https://www.market-scope.com/pages/news/8525/opregen-s-phase-i-iia-trial-in-ga-shows-mean-improvement-in-va-through-36-months-1 https://www.market-scope.com/pages/news/8522/clinical-trial-updates-for-ophthalmic-candidates-july-2025 https://www.market-scope.com/pages/news/8519/emerging-companies-pursuing-ophthalmic-indications-july-2025 https://www.market-scope.com/pages/news/8513/july-2025-ophthalmic-news-briefs https://www.market-scope.com/pages/news/8467/evs-in-ophthalmology-are-all-about-disease-not-driving https://www.market-scope.com/pages/news/8453/emerging-companies-pursuing-ophthalmic-indications-june-2025 https://www.market-scope.com/pages/news/8424/new-scleral-clamp-allows-delivery-of-two-cell-grafts-in-same-eye-for-comparing-effects https://www.market-scope.com/pages/news/8401/ga-patients-in-eyestem-cell-therapy-trial-show-significant-improvement https://www.market-scope.com/pages/news/8348/aurion-biotech-appoints-edward-j-holland-md-as-chief-medical-officer https://www.market-scope.com/pages/news/8345/ga-patients-in-eyestem-phase-i-cell-therapy-trial-show-significant-vision-improvement https://www.market-scope.com/pages/news/8322/alcon-announces-majority-ownership-of-aurion-cell-therapy-company https://www.market-scope.com/pages/news/8279/alcon-announces-majority-ownership-of-aurion https://www.market-scope.com/pages/news/8254/us-fda-approves-neurotech-s-cell-therapy-implant-for-mactel-1 https://www.market-scope.com/pages/news/8231/deerfield-sues-alcon-over-latest-moves-to-prevent-aurion-ipo https://www.market-scope.com/pages/news/8205/us-fda-grants-rmat-designation-for-luxa-s-dry-amd-cell-therapy-candidate https://www.market-scope.com/pages/news/9038/clinical-trial-updates-for-ophthalmic-candidates-march-2026 https://www.market-scope.com/pages/news/9031/us-fda-will-drop-two-study-requirement-for-new-drug-approvals-1 https://www.market-scope.com/pages/news/9026/march-2026-ophthalmic-news-briefs https://www.market-scope.com/pages/news/8987/clinical-trial-updates-for-ophthalmic-candidates-9 https://www.market-scope.com/pages/news/8985/ocular-therapeutix-reports-positive-results-for-axpaxli-vs-eylea-in-phase-iii-wet-amd-trial-1 https://www.market-scope.com/pages/news/8969/february-2026-ophthalmic-news-briefs https://www.market-scope.com/pages/news/8904/ocular-therapeutix-takes-cue-from-fda-will-submit-nda-for-axpaxli-after-single-phase-iii-trial https://www.market-scope.com/pages/news/8906/vivavision-needs-single-us-phase-iii-trial-for-uveitis-nda-fda-says-1 https://www.market-scope.com/pages/news/8910/argenx-pulls-plug-on-thyroid-eye-disease-program-on-recommendation-of-data-monitors-1 https://www.market-scope.com/pages/news/8905/clinical-trial-updates-for-ophthalmic-candidates-january-2026 https://www.market-scope.com/pages/news/8898/january-2026-ophthalmic-news-briefs https://www.market-scope.com/pages/news/8843/precise-bio-implants-world-s-first-3d-bioprinted-cornea-in-patient-in-israel https://www.market-scope.com/pages/news/8841/us-fda-gives-green-light-to-trial-of-eyeyon-s-endoart-artificial-corneal-implant-1 https://www.market-scope.com/pages/news/8831/clinical-trial-updates-for-ophthalmic-candidates-8 https://www.market-scope.com/pages/news/8786/clinical-trial-updates-for-ophthalmic-candidates-november-2025 https://www.market-scope.com/pages/news/8776/november-2025-ophthalmic-news-briefs https://www.market-scope.com/pages/news/8715/kala-to-shut-down-eye-drop-program-for-corneal-defect-after-phase-iib-failure-1 https://www.market-scope.com/pages/news/8714/clinical-trial-updates-for-ophthalmic-candidates-october-2025 https://www.market-scope.com/pages/news/8698/us-fda-gives-green-light-to-trial-of-avisi-s-visiplate-aqueous-shunt-for-glaucoma https://www.market-scope.com/pages/news/8696/ashvattha-names-bob-dempsey-as-interim-ceo https://www.market-scope.com/pages/news/8692/oculis-accelerates-privosegtor-toward-pivotal-trials-in-neuro-ophthalmology https://www.market-scope.com/pages/news/8688/us-fda-gives-green-light-to-phase-i-ii-trial-of-complement-s-ga-gene-therapy-candidate https://www.market-scope.com/pages/news/8684/kala-to-shut-down-eye-drop-program-for-corneal-defect-after-phase-iib-failure https://www.market-scope.com/pages/news/8657/two-european-retina-innovation-meetings-two-audiences https://www.market-scope.com/pages/news/8648/september-2025-ophthalmic-news-briefs https://www.market-scope.com/pages/news/8615/ocumetics-implants-first-patients-in-trial-of-its-accommodating-iol https://www.market-scope.com/pages/news/8600/us-fda-gives-green-light-to-phase-i-ii-trial-of-opus-best1-gene-therapy-candidate https://www.market-scope.com/pages/news/8595/cencora-steps-into-major-role-at-asrs-meeting-following-acquisition https://www.market-scope.com/pages/news/8583/clinical-trial-updates-for-ophthalmic-candidates-august-2025 https://www.market-scope.com/pages/news/8576/august-2025-ophthalmic-news-briefs https://www.market-scope.com/pages/news/8575/myra-vision-gains-ide-approval-to-begin-us-trial-of-adjustable-glaucoma-shunt https://www.market-scope.com/pages/news/8564/regenxbio-plans-pivotal-program-for-dr-gene-therapy-amends-deal-with-abbvie https://www.market-scope.com/pages/news/8549/exonate-plans-phase-iib-trial-of-retinal-eye-drop-candidate-in-npdr https://www.market-scope.com/pages/news/8545/first-patient-treated-in-us-trial-of-eyetronic-optic-nerve-therapy-for-glaucoma https://www.market-scope.com/pages/news/8544/viatris-phase-iii-blepharitis-ointment-candidate-fails-to-reach-primary-endpoint https://www.market-scope.com/pages/news/8535/retina-researchers-urge-jandj-to-file-for-approval-of-xlrp-gene-therapy-despite-failed-trial https://www.market-scope.com/pages/news/8523/presbyopia-drop-candidate-from-viatris-and-opus-meets-endpoints-in-second-phase-iii-trial-1 https://www.market-scope.com/pages/news/8517/iridex-reports-start-of-uk-trial-using-micropulse-with-anti-vegf-injections-in-dme-1 https://www.market-scope.com/pages/news/8503/ocumetics-set-to-begin-first-in-human-study-of-its-accommodating-iol https://www.market-scope.com/pages/news/8504/us-fda-gives-green-light-to-trial-of-aavantgarde-s-stargardt-gene-therapy-candidate https://www.market-scope.com/pages/news/8493/iridex-reports-start-of-uk-trial-using-micropulse-with-anti-vegf-injections-in-dme https://www.market-scope.com/pages/news/8491/opregen-s-phase-i-iia-trial-in-ga-shows-mean-improvement-in-va-through-36-months https://www.market-scope.com/pages/news/8482/presbyopia-drop-candidate-from-viatris-and-opus-meets-endpoints-in-second-phase-iii-trial https://www.market-scope.com/pages/news/8484/us-fda-gives-green-light-to-phase-iii-trial-of-zhaoke-s-cyclosporine-ophthalmic-gel https://www.market-scope.com/pages/news/8473/atia-vision-gains-ide-approval-to-begin-us-trial-of-modular-accommodating-iol-1 https://www.market-scope.com/pages/news/8465/batten-disease-candidate-leads-the-way-in-new-gene-therapy-trials https://www.market-scope.com/pages/news/8463/arvo-attendees-share-concern-over-present-and-future-of-vision-research https://www.market-scope.com/pages/news/8457/clinical-trial-updates-for-ophthalmic-candidates-june-2025 https://www.market-scope.com/pages/news/8449/june-2025-ophthalmic-news-briefs https://www.market-scope.com/pages/news/8441/us-fda-gives-green-light-to-phase-ii-iii-trial-of-ocugen-s-stargardt-candidate https://www.market-scope.com/pages/news/8420/iveena-submits-ind-to-us-fda-for-phase-ii-trial-of-ivmed-85-in-pediatric-myopia https://www.market-scope.com/pages/news/8416/atia-vision-gains-ide-approval-to-begin-us-trial-of-modular-accommodating-iol https://www.market-scope.com/pages/news/8414/us-fda-gives-green-light-to-phase-ii-trial-of-immunoglobulin-eye-drop-from-selagine-grifols https://www.market-scope.com/pages/news/8386/unity-bio-to-cut-workforce-seek-strategic-alternatives-for-ubx1325-in-retina-1 https://www.market-scope.com/pages/news/8384/clinical-trial-updates-for-ophthalmic-candidates-may-2025 https://www.market-scope.com/pages/news/8367/unity-bio-to-cut-workforce-seek-strategic-alternatives-for-ubx1325-in-retina https://www.market-scope.com/pages/news/8361/okyo-pharma-accelerates-development-of-urcosimod-in-neuropathic-corneal-pain https://www.market-scope.com/pages/news/8358/aldeyra-achieves-primary-endpoint-in-phase-iii-dry-eye-chamber-trial-of-reproxalap-plans-nda-resubmission https://www.market-scope.com/pages/news/8328/opthea-discontinues-wet-amd-program-after-second-phase-iii-trial-misses-endpoint https://www.market-scope.com/pages/news/8326/clinical-trial-updates-for-ophthalmic-candidates-april-2025 https://www.market-scope.com/pages/news/8319/us-fda-plans-to-phase-out-animal-testing-for-biologics-drugs-1 https://www.market-scope.com/pages/news/8300/us-fda-plans-to-phase-out-animal-testing-for-biologics-drugs https://www.market-scope.com/pages/news/8298/opthea-will-lay-off-65-percent-of-employees-after-phase-iii-wet-amd-failures https://www.market-scope.com/pages/news/8289/opthea-discontinues-wet-amd-trials-after-second-phase-iii-trial-misses-endpoint https://www.market-scope.com/pages/news/8278/opthea-unity-candidates-miss-clinical-trial-endpoints-vs-aflibercept https://www.market-scope.com/pages/news/8251/changes-in-nih-grant-rules-threaten-to-ripple-through-eye-disease-research https://www.market-scope.com/pages/news/8262/sifi-to-supply-akantior-drops-for-investigator-led-acanthamoeba-keratitis-trial https://www.market-scope.com/pages/news/8252/clinical-trial-updates-for-ophthalmic-candidates-march-2025 https://www.market-scope.com/pages/news/8192/clinical-trial-updates-for-ophthalmic-candidates-february-2025 https://www.market-scope.com/pages/news/8184/february-2025-ophthalmic-news-briefs https://www.market-scope.com/pages/news/8165/outlook-reports-final-results-of-lytenava-trial-plans-bla-resubmission-in-q1-2025 https://www.market-scope.com/pages/news/8140/clinical-trial-updates-for-ophthalmic-candidates-january-2025 https://www.market-scope.com/pages/news/8129/january-2025-ophthalmic-news-briefs https://www.market-scope.com/pages/news/8127/dual-inflammasome-inhibiting-implant-shows-positive-phase-i-ii-results-in-ga https://www.market-scope.com/pages/news/8121/valo-health-suspends-work-on-oral-dr-candidate-after-phase-ii-trial-misses-endpoints https://www.market-scope.com/pages/news/8120/aviceda-raises-207-5-million-in-upsized-series-c-round-to-advance-ga-candidate https://www.market-scope.com/pages/news/8117/us-fda-grants-rare-pediatric-disease-designation-to-vigeneron-s-rp-gene-therapy-candidate https://www.market-scope.com/pages/news/8112/vigeneron-gains-us-fda-green-light-to-begin-phase-i-ii-trial-of-gene-therapy-candidate-for-stargardt https://www.market-scope.com/pages/news/8104/us-fda-gives-green-light-to-phase-i-ii-trial-of-splicebio-s-protein-splicing-gene-therapy-candidate-for-stargardt https://www.market-scope.com/pages/news/8095/acelyrin-s-izokibep-misses-endpoints-in-phase-iib-iii-uveitis-trial https://www.market-scope.com/pages/news/8080/eyenovia-scraps-phase-iii-study-of-low-dose-atropine-candidate-in-myopia https://www.market-scope.com/pages/news/8082/clinical-trial-updates-for-ophthalmic-candidates-december-2024 https://www.market-scope.com/pages/news/8066/outlook-s-lytenava-misses-endpoint-vs-ranibizumab-in-topline-results-1 https://www.market-scope.com/pages/news/iol https://www.market-scope.com/pages/news/premium https://www.market-scope.com/pages/news/flacs https://www.market-scope.com/pages/news/8973/surging-economy-aging-population-to-fuel-growth-in-india-s-ophthalmic-market-through-2030 https://www.market-scope.com/pages/news/8975/dropless-cataract-surgery-gets-a-boost-as-interest-data-align https://www.market-scope.com/pages/news/9034/apao-congress-looks-at-improving-the-quality-of-cataract-surgery https://www.market-scope.com/pages/news/8919/2025-in-review-alcon-launches-two-new-platforms-unity-and-voyager https://www.market-scope.com/pages/news/8921/2025-in-review-bausch-and-lomb-bounces-back-from-iol-recall-plans-busy-launch-schedule https://www.market-scope.com/pages/news/8922/2025-in-review-corporate-and-surgeon-rankings-of-top-10-stories https://www.market-scope.com/pages/news/8911/2025-in-review-next-generation-pc-iol-designs-drive-global-market-expansion-in-2025 https://www.market-scope.com/pages/news/8852/bascom-palmer-eye-institute-opens-location-in-abu-dhabi-1 https://www.market-scope.com/pages/news/8849/select-us-fda-approvals-and-clearances-in-november-2025 https://www.market-scope.com/pages/news/8775/harrow-takes-unconventional-path-sees-soaring-revenue-growth https://www.market-scope.com/pages/news/8832/ophthalmic-company-revenue-drops-4-5-percent-in-third-quarter-of-2025 https://www.market-scope.com/pages/news/8789/amsurg-acquires-asc-in-south-carolina-expanding-footprint-in-state-1 https://www.market-scope.com/pages/news/8834/emerging-companies-pursuing-ophthalmic-indications-december-2025 https://www.market-scope.com/pages/news/8795/numerous-new-products-showcased-at-2025-aao-meeting https://www.market-scope.com/pages/news/8782/weekly-ophthalmologist-and-optometrist-poll-november-2025 https://www.market-scope.com/pages/news/8728/rayner-gains-us-fda-approval-of-rayone-emv-toric-iol-1 https://www.market-scope.com/pages/news/8727/bvi-s-finevision-hp-trifocal-iol-gains-us-fda-approval-rollout-set-for-2026 https://www.market-scope.com/pages/news/8730/premium-cataract-surgery-growth-increasingly-led-by-international-markets https://www.market-scope.com/pages/news/8790/how-two-cms-cuts-affect-final-2026-physician-fee-schedule https://www.market-scope.com/pages/news/8710/harrow-agrees-to-reacquire-melt-pharmaceuticals-1 https://www.market-scope.com/pages/news/8708/october-2025-ophthalmic-news-briefs https://www.market-scope.com/pages/news/8725/select-us-fda-approvals-and-clearances-in-september-2025 https://www.market-scope.com/pages/news/8707/bvi-medical-s-finevision-hp-trifocal-iol-gains-us-fda-approval https://www.market-scope.com/pages/news/8695/rayner-gains-us-fda-approval-of-rayone-emv-toric-iol https://www.market-scope.com/pages/news/8702/biotech-healthcare-launches-optiflex-xtense-comfort-plus-edof-iol-in-europe https://www.market-scope.com/pages/news/8669/ophthalmologists-report-2-2-percent-increase-in-q2-2025-procedure-volume https://www.market-scope.com/pages/news/8673/horizon-surgical-systems-names-rajesh-rajpal-md-as-cmo-cso https://www.market-scope.com/pages/news/8680/harrow-agrees-to-reacquire-melt-pharmaceuticals https://www.market-scope.com/pages/news/8624/bvi-launches-virtuoso-dual-function-cataract-vitrectomy-system-in-europe https://www.market-scope.com/pages/news/8666/select-us-fda-approvals-and-clearances-in-august-2025 https://www.market-scope.com/pages/news/8636/1-million-champalimaud-vision-award-goes-to-three-prominent-eye-charities https://www.market-scope.com/pages/news/8597/sustainability-movement-gains-traction-impacts-growth-in-reusable-instruments https://www.market-scope.com/pages/news/8574/q2-2025-ophthalmic-revenue-roundup-for-tarsus-immunocore-harrow-ani-sight-sciences-and-iridex https://www.market-scope.com/pages/news/8605/q2-2025-ophthalmic-revenue-roundup-for-alcon-carl-zeiss-meditec-opus-and-outlook https://www.market-scope.com/pages/news/8568/vsy-biotechnology-launches-enova-hydrophobic-iols-with-rotaryjet-inserter https://www.market-scope.com/pages/news/8593/cms-proposes-lower-physician-payments-in-2026-higher-hopd-and-asc-fees-1 https://www.market-scope.com/pages/news/8540/onconetix-to-merge-with-glaucoma-drop-maker-ocuvex https://www.market-scope.com/pages/news/8557/cms-proposes-lower-physician-payments-in-2026-higher-hopd-and-asc-fees https://www.market-scope.com/pages/news/8558/q2-2025-ophthalmic-revenue-roundup-for-roche-bausch-and-lomb-apellis-glaukos-and-astellas https://www.market-scope.com/pages/news/8529/select-us-fda-approvals-and-clearances-in-june-2025 https://www.market-scope.com/pages/news/8518/alcon-aims-to-extend-ultrasonic-phaco-dominance-with-launch-of-unity-cs https://www.market-scope.com/pages/news/8526/jandj-vision-launches-tecnis-odyssey-pc-iol-in-europe-middle-east-and-canada-1 https://www.market-scope.com/pages/news/8510/jandj-vision-generates-q2-2025-surgical-revenue-of-403-million https://www.market-scope.com/pages/news/8534/forsight-leads-latest-ophthalmic-fundraising-with-125-million-in-series-b https://www.market-scope.com/pages/news/8499/rxsight-lowers-2025-guidance-due-to-q2-2025-preliminary-results https://www.market-scope.com/pages/news/8514/weekly-surgeon-poll-july-2025 https://www.market-scope.com/pages/news/8496/alcon-unity-vcs-dual-function-system-gains-approval-in-canada https://www.market-scope.com/pages/news/8505/israel-s-painreform-enters-ophthalmology-with-investment-in-layerbio https://www.market-scope.com/pages/news/8488/donor-gives-40m-to-ophthalmology-department-at-cu-anschutz-in-colorado https://www.market-scope.com/pages/news/8479/health-insurers-pledge-to-reform-prior-authorization-by-2026 https://www.market-scope.com/pages/news/8476/alcon-unity-cataract-and-dual-function-systems-gain-approval-in-brazil https://www.market-scope.com/pages/news/8492/cms-to-increase-audits-of-medicare-advantage-billing-to-prevent-upcoding https://www.market-scope.com/pages/news/8458/harrow-acquires-us-rights-to-formosa-s-clobetasol-now-branded-byqlovi-1 https://www.market-scope.com/pages/news/8483/vivavision-us-fda-agree-on-accelerated-path-for-post-op-inflammation-candidate https://www.market-scope.com/pages/news/8446/jandj-vision-launches-tecnis-odyssey-pc-iol-in-europe-middle-east-and-canada https://www.market-scope.com/pages/news/8450/weekly-corporate-and-surgeon-polls-june-2025 https://www.market-scope.com/pages/news/8428/essilorluxottica-to-acquire-european-ophthalmology-clinic-chain-optegra https://www.market-scope.com/pages/news/8474/essilorluxottica-to-acquire-european-ophthalmology-clinic-chain-optegra-1 https://www.market-scope.com/pages/news/8440/harrow-acquires-us-rights-to-formosa-s-clobetasol-now-branded-byqlovi https://www.market-scope.com/pages/news/8374/x-rounds-session-provides-rapid-fire-insights-on-what-s-hot-what-s-not https://www.market-scope.com/pages/news/8419/formosa-licenses-clobetasol-drops-to-adalvo-for-european-brazilian-markets https://www.market-scope.com/pages/news/8385/bausch-and-lomb-ends-recall-of-envista-iols-after-tracking-source-of-contamination-1 https://www.market-scope.com/pages/news/8415/q1-2025-ophthalmic-revenue-roundup-for-bausch-and-lomb-and-carl-zeiss-meditec https://www.market-scope.com/pages/news/8404/alcon-emphasizes-efficiency-of-unity-vcs-and-cs-systems-at-ascrs-launch https://www.market-scope.com/pages/news/8402/alcon-launches-panoptix-pro-trifocal-lens-at-2025-ascrs-meeting https://www.market-scope.com/pages/news/8377/ascrs-panel-examines-digital-visualization-s-ergonomics-and-efficiency https://www.market-scope.com/pages/news/8405/zeiss-veracity-surgery-planner-driving-innovation-in-cataract-care https://www.market-scope.com/pages/news/8391/maximilian-foerst-to-lead-carl-zeiss-meditec-markus-weber-phd-steps-down https://www.market-scope.com/pages/news/8400/rayner-s-sophi-zeiss-micor-700-showcased-at-the-2025-ascrs-meeting https://www.market-scope.com/pages/news/8376/weekly-surgeon-poll-may-2025 https://www.market-scope.com/pages/news/8389/ballooning-nhs-cataract-surgery-costs-at-private-clinics-raise-red-flags-1 https://www.market-scope.com/pages/news/8370/bausch-and-lomb-receives-ce-marking-for-preloaded-luxlife-trifocal-iol https://www.market-scope.com/pages/news/8387/laws-in-montana-west-virginia-expand-ods-scope-to-include-laser https://www.market-scope.com/pages/news/8372/q1-2025-ophthalmic-revenue-roundup-for-alcon-immunocore-harrow-sight-sciences-ani-iridex-and-xbrane https://www.market-scope.com/pages/news/8366/maximilian-foerst-to-lead-carl-zeiss-meditec-as-markus-weber-phd-steps-down https://www.market-scope.com/pages/news/8375/may-2025-ophthalmic-news-briefs https://www.market-scope.com/pages/news/8363/q1-2025-ophthalmic-revenue-roundup-for-amgen-hoya-apellis-tarsus-staar-rxsight-and-ocular-therapeutix https://www.market-scope.com/pages/news/8346/bausch-and-lomb-ends-recall-of-envista-iols-after-tracking-source-of-contamination https://www.market-scope.com/pages/news/8352/formosa-licenses-clobetasol-propionate-drops-to-chile-s-saval-for-latin-america https://www.market-scope.com/pages/news/8339/new-mexico-governor-vetoes-bill-to-allow-ods-to-perform-slt-yag-capsulotomy https://www.market-scope.com/pages/news/8343/alcon-rolls-out-unity-vcs-and-cs-systems-at-ascrs-meeting https://www.market-scope.com/pages/news/8316/alcon-agrees-to-buy-lensar-in-deal-worth-up-to-430-million-1 https://www.market-scope.com/pages/news/8340/ballooning-nhs-cataract-surgery-costs-at-private-clinics-raise-red-flags https://www.market-scope.com/pages/news/8321/bausch-and-lomb-recalls-certain-envista-iols-amid-reports-of-tass-cases-1 https://www.market-scope.com/pages/news/8318/alcon-introduces-clareon-panoptix-pro-iol https://www.market-scope.com/pages/news/8312/better-iols-push-from-surgeons-will-drive-healthy-premium-growth https://www.market-scope.com/pages/news/8302/jandj-vision-reports-q1-2025-surgical-revenue-of-361-million https://www.market-scope.com/pages/news/8293/us-fda-issues-update-on-bausch-and-lomb-envista-iol-recall https://www.market-scope.com/pages/news/8309/april-2025-ophthalmic-news-briefs https://www.market-scope.com/pages/news/8290/onconetix-signs-letter-of-intent-for-potential-business-combination-with-ocuvex https://www.market-scope.com/pages/news/8285/alcon-introduces-clareon-panoptix-pro-trifocal-iol https://www.market-scope.com/pages/news/8272/alcon-agrees-to-buy-lensar-in-deal-worth-up-to-430-million https://www.market-scope.com/pages/news/8277/alcon-announces-ce-mark-approval-european-launch-of-clareon-vivity-iol https://www.market-scope.com/pages/news/8282/rayner-doubles-iol-manufacturing-capacity-with-expansion-of-facility https://www.market-scope.com/pages/news/8280/bausch-and-lomb-recalls-certain-envista-iols-amid-reports-of-tass-cases https://www.market-scope.com/pages/news/8239/bvi-leads-latest-ophthalmic-fundraising-with-1-billion-in-strategic-capital https://www.market-scope.com/pages/news/8203/select-us-fda-approvals-and-clearances-in-january-2025 https://www.market-scope.com/pages/news/8228/2024-ophthalmic-revenue-roundup-for-apellis-immunocore-sight-sciences-ocular-therapeutix-lensar-and-ani https://www.market-scope.com/pages/news/8189/retrospective-study-finds-link-between-ivt-injections-cataract-surgery-complications-1 https://www.market-scope.com/pages/news/8221/2024-ophthalmic-revenue-roundup-for-alcon-glaukos-tarsus-and-rxsight https://www.market-scope.com/pages/news/8182/2024-and-quarterly-ophthalmic-revenue-roundup-for-regeneron-carl-zeiss-meditec-hoya-and-staar https://www.market-scope.com/pages/news/8162/retrospective-study-finds-link-between-ivt-injections-cataract-surgery-complications https://www.market-scope.com/pages/news/8186/weekly-surgeon-polls-february-2025 https://www.market-scope.com/pages/news/8158/health-canada-approves-rayner-s-rayone-emv-toric-iol https://www.market-scope.com/pages/news/8130/2024-in-review-zeiss-rollout-of-micor-700-shakes-up-cataract-equipment-market-in-us https://www.market-scope.com/pages/news/8153/2024-in-review-newest-pc-iols-helped-drive-worldwide-growth-in-2024 https://www.market-scope.com/pages/news/8150/2024-in-review-corporate-and-surgeon-rankings-of-top-10-stories https://www.market-scope.com/pages/news/8137/bausch-kicks-off-2025-with-series-of-research-deals-plus-an-iol-launch https://www.market-scope.com/pages/news/8132/weekly-surgeon-poll-january-2025 https://www.market-scope.com/pages/news/8131/johns-hopkins-scientists-develop-clear-ovd-that-glows-under-blue-light-1 https://www.market-scope.com/pages/news/8113/ophthalmic-revenue-roundup-for-carl-zeiss-meditec-amgen-biogen https://www.market-scope.com/pages/news/8101/johns-hopkins-scientists-develop-clear-ovd-that-glows-under-blue-light https://www.market-scope.com/pages/news/8090/nidek-launches-np-t-preloaded-toric-iol-injector-globally https://www.market-scope.com/pages/news/ocular-surface https://www.market-scope.com/pages/news/8077/lineage-leads-latest-ophthalmic-fundraising-with-66-million-offering https://www.market-scope.com/pages/news/8912/2025-in-review-multiple-cornea-therapeutic-milestones-achieved-in-late-2025 https://www.market-scope.com/pages/news/8840/birth-tissue-grafts-are-experiencing-immense-momentum-as-cornea-treatment https://www.market-scope.com/pages/news/8072/cms-cuts-ophthalmologists-procedure-fees-while-raising-asc-hopd-facility-fees-1 https://www.market-scope.com/pages/news/8845/cellution-launches-amnioplast-allografts-in-us-for-ocular-surface-repair-1 https://www.market-scope.com/pages/news/8848/belite-leads-latest-ophthalmic-fundraising-with-350-million-offering https://www.market-scope.com/pages/news/8842/two-leading-eye-banks-based-in-southeastern-us-announce-merger-1 https://www.market-scope.com/pages/news/8783/moria-s-new-corneal-tissue-storage-medium-is-first-in-decades https://www.market-scope.com/pages/news/8726/us-fda-approves-glaukos-epioxa-epi-on-crosslinking-therapy-for-keratoconus https://www.market-scope.com/pages/news/8703/epion-therapeutics-forms-strategic-partnership-with-oculus https://www.market-scope.com/pages/news/8668/pdufa-dates-for-ophthalmic-drug-candidates-september-2025 https://www.market-scope.com/pages/news/8778/emerging-companies-pursuing-ophthalmic-indications-november-2025 https://www.market-scope.com/pages/news/8665/researchers-see-early-promise-in-electromechanical-reshaping-of-cornea-1 https://www.market-scope.com/pages/news/8641/moria-s-donor-cornea-storage-medium-xtra4-gains-us-fda-510-k-clearance https://www.market-scope.com/pages/news/8634/xpanceo-and-intra-ker-unveil-corneal-implant-that-projects-images-onto-retina https://www.market-scope.com/pages/news/8630/todd-bazemore-becomes-kala-president-and-ceo-will-take-seat-on-board https://www.market-scope.com/pages/news/8604/researchers-see-early-promise-in-electromechanical-reshaping-of-cornea https://www.market-scope.com/pages/news/8532/eyedura-wins-two-octane-awards-for-sustained-release-eye-drop-platform https://www.market-scope.com/pages/news/8516/pdufa-dates-for-ophthalmic-drug-candidates-july-2025 https://www.market-scope.com/pages/news/8506/eyedura-and-its-eye-drop-platform-continue-to-win-honors-from-accelerators https://www.market-scope.com/pages/news/8464/spain-s-faes-farma-acquires-italy-s-sifi-in-deal-worth-310-4-million-1 https://www.market-scope.com/pages/news/8452/pdufa-dates-for-ophthalmic-drug-candidates-june-2025 https://www.market-scope.com/pages/news/8439/spain-s-faes-farma-acquires-italy-s-sifi-in-deal-worth-310-4-million https://www.market-scope.com/pages/news/8418/allotex-launches-refractive-corneal-implant-in-canada https://www.market-scope.com/pages/news/8411/sifi-gains-marketing-authorization-pim-designation-for-akantior-drops-in-uk https://www.market-scope.com/pages/news/8378/emerging-companies-pursuing-ophthalmic-indications-may-2025 https://www.market-scope.com/pages/news/8354/q1-2025-ophthalmic-revenue-roundup-for-roche-regeneron-abbvie-glaukos-lumibird-and-biogen https://www.market-scope.com/pages/news/8347/design-therapeutics-appoints-chris-m-storgard-md-as-chief-medical-officer https://www.market-scope.com/pages/news/8342/veo-launches-plexitome-to-treat-recurrent-corneal-erosion-corneal-abrasions https://www.market-scope.com/pages/news/8337/senju-licenses-brill-s-non-contact-esthesiometer-for-japan https://www.market-scope.com/pages/news/8299/acro-biomedical-gains-regulatory-approval-in-taiwan-for-corneal-xenograft https://www.market-scope.com/pages/news/8275/surrozen-to-focus-on-ophthalmic-pipeline-raises-up-to-175-million-in-private-placement https://www.market-scope.com/pages/news/8274/pantheon-eyedeal-medical-to-collaborate-on-bioengineered-corneal-implant https://www.market-scope.com/pages/news/8265/bausch-and-lomb-launches-arise-orthokeratology-lens-fitting-system-in-the-us https://www.market-scope.com/pages/news/8261/pdufa-dates-for-ophthalmic-drug-candidates-1 https://www.market-scope.com/pages/news/8256/us-fda-accepts-nda-for-glaukos-epioxa-for-epi-on-crosslinking-therapy https://www.market-scope.com/pages/news/8246/deerfield-sues-alcon-over-latest-moves-to-prevent-aurion-ipo-1 https://www.market-scope.com/pages/news/8245/study-of-corneal-stem-cell-transplant-shows-vision-restored-after-injury https://www.market-scope.com/pages/news/8234/study-of-corneal-stem-cell-transplant-shows-vision-restored-after-blinding-eye-injuries https://www.market-scope.com/pages/news/8220/us-fda-accepts-nda-for-glaukos-epioxa-sets-pdufa-date-of-oct-20-2025 https://www.market-scope.com/pages/news/8177/kala-bio-s-ceo-resigns-president-coo-takes-over-as-interim https://www.market-scope.com/pages/news/8164/aurion-plans-to-launch-ipo-alcon-loses-court-bid-to-stop-move https://www.market-scope.com/pages/news/8143/glaukos-submits-nda-for-epioxa-epi-on-crosslinking-treatment-1 https://www.market-scope.com/pages/news/8148/aviceda-leads-latest-ophthalmic-fundraising-with-207-5-million-round https://www.market-scope.com/pages/news/8136/carter-s-many-accomplishments-include-saving-millions-from-blindness-1 https://www.market-scope.com/pages/news/8133/emerging-companies-pursuing-ophthalmic-indications-january-2025 https://www.market-scope.com/pages/news/8110/sightstream-is-developing-an-eye-drop-candidate-for-corneal-endothelial-disease https://www.market-scope.com/pages/news/8107/carter-s-many-accomplishments-include-saving-millions-from-blindness https://www.market-scope.com/pages/news/8106/glaukos-submits-nda-for-epioxa-epi-on-crosslinking-treatment https://www.market-scope.com/pages/news/8103/provectus-launches-visirose-to-commercialize-rose-bengal-antimicrobial-light-treatments https://www.market-scope.com/pages/news/8091/sifi-files-for-uk-approval-of-akantior-drops-for-acanthamoeba-keratitis https://www.market-scope.com/pages/news/8079/cornea-transplant-market-continues-to-face-procurement-challenges-as-new-approaches-on-rise https://www.market-scope.com/pages/news/9033/ccoi-s-innovation-meeting-shines-light-on-untapped-assets-in-china https://www.market-scope.com/pages/news/8788/novartis-offloads-rights-to-beovu-lucentis-in-south-korea-china https://www.market-scope.com/pages/news/8900/kodiak-leads-latest-ophthalmic-fundraising-with-184-million-offering https://www.market-scope.com/pages/news/8694/nova-eye-s-itrack-advance-canaloplasty-device-approved-in-china https://www.market-scope.com/pages/news/8830/december-2025-ophthalmic-news-briefs https://www.market-scope.com/pages/news/8719/nova-eye-s-itrack-advance-canaloplasty-device-approved-in-china-1 https://www.market-scope.com/pages/news/8515/chinese-companies-launch-wave-of-new-ophthalmic-products-at-home https://www.market-scope.com/pages/news/8689/regulators-in-china-accept-bla-for-dme-candidate-from-santen-remegen https://www.market-scope.com/pages/news/8601/santen-licenses-remegen-s-retinal-candidate-for-greater-china-asian-countries https://www.market-scope.com/pages/news/8437/chinese-regulators-approve-clarus-700-ultra-widefield-fundus-camera-from-zeiss https://www.market-scope.com/pages/news/8425/bayer-receives-approval-in-china-for-high-dose-eylea-in-wet-amd https://www.market-scope.com/pages/news/8501/chinese-regulators-approve-perfluorohexyloctane-drops-for-dry-eye-with-mgd https://www.market-scope.com/pages/news/8307/combined-apao-aios-meeting-draws-12-500-to-new-convention-center-in-india https://www.market-scope.com/pages/news/8486/uni-bio-gains-approval-in-china-for-diquafosol-sodium-eye-drops-for-dry-eye https://www.market-scope.com/pages/news/8308/asia-pacific-leads-push-to-get-ai-from-the-bench-to-the-bedside https://www.market-scope.com/pages/news/8276/chinese-regulators-approve-dorc-s-ilm-blue-ocular-dye https://www.market-scope.com/pages/news/8270/chinese-regulators-approve-innovent-s-sycume-for-thyroid-eye-disease https://www.market-scope.com/pages/news/8237/march-2025-ophthalmic-news-briefs https://www.market-scope.com/pages/news/8217/chinese-regulators-approve-zeiss-visumax-800-with-smile-pro-software https://www.market-scope.com/pages/news/8291/chinese-regulators-approve-tapcom-fixed-combo-glaucoma-drop-from-santen https://www.market-scope.com/pages/news/8214/chinese-regulators-accept-nda-for-arcatus-xipere-in-uveitic-macular-edema https://www.market-scope.com/pages/news/8253/chinese-regulators-approve-zeiss-visumax-800-with-smile-pro-software-1 https://www.market-scope.com/pages/news/8168/chinese-regulators-accept-marketing-application-for-zhaoke-s-low-dose-atropine-drop-for-myopia https://www.market-scope.com/pages/news/8083/arctic-vision-licenses-chinese-rights-for-xipere-to-santen-for-85-million-1 https://www.market-scope.com/pages/news/8119/eyebright-medical-gains-certification-in-china-for-phakic-iol https://www.market-scope.com/pages/news/oct https://www.market-scope.com/pages/news/8089/nicox-reports-first-sale-of-zerviate-in-china-by-partner-ocumension https://www.market-scope.com/pages/news/microscopes https://www.market-scope.com/pages/news/fundus https://www.market-scope.com/pages/news/perimetry https://www.market-scope.com/pages/news/oculomics https://www.market-scope.com/pages/news/8978/nidek-launches-phantom-open-field-refraction-system https://www.market-scope.com/pages/news/8980/select-us-fda-approvals-and-clearances-in-january-2026 https://www.market-scope.com/pages/news/8981/american-college-of-eye-technicians-offers-fast-track-virtual-training-program-1 https://www.market-scope.com/pages/news/8908/select-us-fda-approvals-and-clearances-in-december-2025 https://www.market-scope.com/pages/news/8914/2025-in-review-essilorluxottica-entrenches-ophthalmic-strategy-with-2025-deals https://www.market-scope.com/pages/news/8717/digital-slit-lamp-technology-gains-high-praise-in-copenhagen https://www.market-scope.com/pages/news/8721/essilorluxottica-acquires-screening-software-company-retinai-1 https://www.market-scope.com/pages/news/8704/essilorluxottica-acquires-screening-software-company-retinai https://www.market-scope.com/pages/news/8711/emerging-companies-pursuing-ophthalmic-indications-october-2025 https://www.market-scope.com/pages/news/8706/optos-launches-the-silverstone-rgb-advanced-retinal-imaging-system https://www.market-scope.com/pages/news/8700/konan-medical-s-objectivefield-perimeter-gains-ce-marking https://www.market-scope.com/pages/news/8697/retinalgenix-partners-with-genotyping-lab-on-disease-detection-through-the-eye https://www.market-scope.com/pages/news/8701/ocusciences-ocumet-beacon-retinal-imager-gains-ce-marking https://www.market-scope.com/pages/news/8674/topcon-launches-tera-imager-for-detection-and-management-of-dry-eye https://www.market-scope.com/pages/news/8650/ai-integration-and-workflow-consolidation-drive-diagnostic-innovation https://www.market-scope.com/pages/news/8655/former-lumithera-diagnostic-business-relaunches-as-opzira-after-alcon-deal-1 https://www.market-scope.com/pages/news/8629/haag-streit-announces-appointment-of-thomas-lenzen-as-ceo https://www.market-scope.com/pages/news/8621/former-lumithera-diagnostic-business-relaunches-as-opzira-after-alcon-deal https://www.market-scope.com/pages/news/8617/zeiss-gains-ce-marking-for-cirrus-pathfinder-ai-tool-with-automated-oct-analysis https://www.market-scope.com/pages/news/8612/quarterly-ophthalmic-revenue-roundup-for-santen-lumibird-biogen-and-xbrane https://www.market-scope.com/pages/news/8589/select-us-fda-approvals-and-clearances-in-july-2025 https://www.market-scope.com/pages/news/8584/topcon-acquires-retinal-screening-platform-to-improve-bidirectional-referrals https://www.market-scope.com/pages/news/8572/moran-celebrates-approval-of-ai-tech-to-help-time-injections-for-wet-amd https://www.market-scope.com/pages/news/8563/topcon-healthcare-acquires-retinal-screening-platform-to-improve-bidirectional-referrals https://www.market-scope.com/pages/news/8580/emerging-companies-pursuing-ophthalmic-indications-august-2025 https://www.market-scope.com/pages/news/8561/aeye-health-appoints-pamela-f-gallin-md-as-chief-medical-officer https://www.market-scope.com/pages/news/8530/baruch-kuppermann-md-phd-receives-2025-roger-steinert-md-legacy-award https://www.market-scope.com/pages/news/8520/dews-iii-report-updates-guidelines-for-diagnosis-and-management-of-dry-eye https://www.market-scope.com/pages/news/8485/zilia-gains-approval-in-canada-for-its-fundus-camera-with-ocular-oximetry https://www.market-scope.com/pages/news/8472/select-us-fda-approvals-and-clearances-in-may-2025 https://www.market-scope.com/pages/news/8422/eyego-developer-of-digital-ophthalmic-microdoser-secures-strategic-investment-from-topcon https://www.market-scope.com/pages/news/8421/deepeye-tps-ai-support-tool-for-wet-amd-treatment-gains-ce-marking https://www.market-scope.com/pages/news/8390/intalight-receives-ce-marking-for-dream-oct-swept-source-imaging-1 https://www.market-scope.com/pages/news/8392/select-us-fda-approvals-and-clearances-in-april-2025 https://www.market-scope.com/pages/news/8399/therini-bio-leads-latest-ophthalmic-fundraising-with-39-million-in-series-a https://www.market-scope.com/pages/news/8371/intalight-receives-ce-marking-for-dream-oct-swept-source-imaging https://www.market-scope.com/pages/news/8364/topcon-healthcare-acquires-retinsight-to-advance-ai-powered-imaging-in-eye-care https://www.market-scope.com/pages/news/8360/us-fda-grants-marketing-clearance-for-ocusciences-ocumet-beacon-retinal-imager https://www.market-scope.com/pages/news/8359/retinai-and-fvs-gain-ce-marking-for-luxia-dr-screening-algorithm https://www.market-scope.com/pages/news/8325/select-us-fda-approvals-and-clearances-in-march-2025 https://www.market-scope.com/pages/news/8317/topcon-to-go-private-through-tender-offer-by-kkr-and-jic-capital-1 https://www.market-scope.com/pages/news/8315/emerging-companies-pursuing-ophthalmic-indications-april-2025 https://www.market-scope.com/pages/news/8283/topcon-to-go-private-through-tender-offer-by-kkr-and-jic-capital https://www.market-scope.com/pages/news/8273/zeiss-launches-visulas-combi-in-canada https://www.market-scope.com/pages/news/8257/topcon-radiusxr-and-glaukos-team-up-to-launch-inspire-vr-perimeter-headset-1 https://www.market-scope.com/pages/news/8259/optos-unveils-monacopro-ultra-widefield-retinal-imager-with-sd-oct-1 https://www.market-scope.com/pages/news/8241/emerging-companies-pursuing-ophthalmic-indications-march-2025 https://www.market-scope.com/pages/news/8233/topcon-radiusxr-and-glaukos-team-up-to-launch-inspire-vr-perimeter-headset https://www.market-scope.com/pages/news/8215/seonix-bio-launches-sightscore-saliva-test-for-glaucoma-risk-in-us https://www.market-scope.com/pages/news/8207/optos-unveils-monacopro-ultra-widefield-retinal-imager-with-sd-oct https://www.market-scope.com/pages/news/8198/essilorluxottica-acquires-canadian-retinal-camera-maker-cellview-imaging-for-undisclosed-amount https://www.market-scope.com/pages/news/8202/oculis-leads-latest-ophthalmic-fundraising-with-100-million-offering https://www.market-scope.com/pages/news/8197/global-oct-market-poised-for-strong-growth-thanks-to-add-ons-for-combination-devices https://www.market-scope.com/pages/news/8196/inventors-of-oct-to-be-inducted-into-national-inventors-hall-of-fame-1 https://www.market-scope.com/pages/news/8181/essilorluxottica-acquires-canadian-retinal-camera-maker-cellview-imaging https://www.market-scope.com/pages/news/8157/inventors-of-oct-to-be-inducted-into-national-inventors-hall-of-fame https://www.market-scope.com/pages/news/8139/select-us-fda-approvals-and-clearances-in-december-2024 https://www.market-scope.com/pages/news/8141/2024-in-review-warburg-pincus-buys-controlling-stake-in-india-s-appasamy https://www.market-scope.com/pages/news/8116/eyenuk-appoints-gaurav-agarwal-as-chief-executive-officer https://www.market-scope.com/pages/news/8100/nih-joins-push-to-fund-breakthroughs-in-oculomics https://www.market-scope.com/pages/news/8081/konan-medical-launches-objectivefield-perimeter-in-the-us https://www.market-scope.com/pages/news/8087/topcon-weighing-takeover-bids-from-private-equity-firms-bloomberg-reports-1 https://www.market-scope.com/pages/news/8097/500-thousand-arizona-students-get-vision-screening-thanks-to-new-law https://www.market-scope.com/pages/news/8088/nih-joins-push-to-fund-breakthroughs-in-oculomics-diagnostic-tech https://www.market-scope.com/pages/news/8067/emerging-companies-pursuing-ophthalmic-indications-december-2024 https://www.market-scope.com/pages/news/8059/topcon-weighing-takeover-bids-from-private-equity-firms-bloomberg-reports https://www.market-scope.com/pages/news/9028/weekly-poll-of-mds-and-ods-march-2026 https://www.market-scope.com/pages/news/8977/eu-india-free-trade-agreement-to-phase-in-lower-pharma-and-device-tariffs-1 https://www.market-scope.com/pages/news/8838/dry-eye-device-field-gets-more-crowded-with-product-launches https://www.market-scope.com/pages/news/8705/iantrek-announces-us-commercial-launch-of-alloflo-uveo-biostent-for-glaucoma https://www.market-scope.com/pages/news/8659/euretina-presentations-included-surprises-on-vitreous-cutters-pbm-treatment https://www.market-scope.com/pages/news/8502/alcon-to-acquire-lumithera-and-its-photobiomodulation-device-for-dry-amd https://www.market-scope.com/pages/news/8331/malvina-eydelman-md-named-ceo-of-ccoi-organization-1 https://www.market-scope.com/pages/news/8286/malvina-eydelman-md-named-ceo-of-ccoi-organization https://www.market-scope.com/pages/news/8258/retina-surgeons-ready-for-alcon-to-make-a-splash-with-unity-vcs https://www.market-scope.com/pages/news/8147/2024-in-review-lumithera-s-valeda-is-first-treatment-for-early-intermediate-dry-amd https://www.market-scope.com/pages/news/8138/essilorluxottica-to-acquire-ophthalmic-device-maker-espansione-group https://www.market-scope.com/pages/news/8118/low-vision-devices-including-one-similar-to-a-fly-s-eye-highlighted-at-ces-2025 https://www.market-scope.com/pages/news/8111/essilorluxottica-to-acquire-espansione-group-maker-of-ophthalmic-devices https://www.market-scope.com/pages/news/data-security https://www.market-scope.com/pages/news/ai https://www.market-scope.com/pages/news/telehealth https://www.market-scope.com/pages/news/8468/latest-ai-discussions-drill-down-to-nuts-and-bolts-and-concerns https://www.market-scope.com/pages/news/8383/topcon-healthcare-acquires-retinsight-to-advance-ai-powered-imaging-in-eye-care-1 https://www.market-scope.com/pages/news/acquisitions https://www.market-scope.com/pages/news/revenue https://www.market-scope.com/pages/news/earnings https://www.market-scope.com/pages/news/mergers https://www.market-scope.com/pages/news/private-equity https://www.market-scope.com/pages/news/8984/samsung-bioepis-deals-with-regeneron-clear-way-for-eylea-biosimilar https://www.market-scope.com/pages/news/emerging https://www.market-scope.com/pages/news/8901/venture-capital-in-ophthalmology-doubled-in-2025-to-just-under-2-billion https://www.market-scope.com/pages/news/8899/2025-in-review-staar-calls-off-alcon-acquisition-deal-after-failed-vote-by-shareholders https://www.market-scope.com/pages/news/funding https://www.market-scope.com/pages/news/8903/alvotech-teva-reach-deal-with-regeneron-to-bring-eylea-biosimilar-to-us-no-later-than-h2-2026 https://www.market-scope.com/pages/news/8920/lenz-signs-deal-with-lunatus-for-marketing-of-vizz-in-middle-east-1 https://www.market-scope.com/pages/news/8847/iolyx-licenses-autoimmune-dry-eye-candidate-to-thea-in-deal-worth-up-to-280-million-1 https://www.market-scope.com/pages/news/8853/alcon-raises-bid-for-staar-large-shareholders-continue-to-oppose-deal https://www.market-scope.com/pages/news/8729/alcon-staar-deal-up-in-the-air-as-shareholder-vote-is-delayed https://www.market-scope.com/pages/news/8787/lilly-makes-foray-into-ophthalmic-gene-therapies-with-adverum-meiragtx-deals https://www.market-scope.com/pages/news/8723/retinal-pharma-deals-drive-ophthalmic-fundraising-in-q3-2025 https://www.market-scope.com/pages/news/8699/us-fda-approves-celltrion-s-aflibercept-biosimilar-branded-eydenzelt https://www.market-scope.com/pages/news/8797/staar-solicits-new-bids-under-amended-deal-with-alcon-moves-shareholder-vote-to-dec-19-1 https://www.market-scope.com/pages/news/8678/visufarma-becomes-part-of-india-s-lupin-limited https://www.market-scope.com/pages/news/8687/vivani-delays-record-date-for-cortigent-spinoff-due-to-shutdown https://www.market-scope.com/pages/news/8677/staar-counters-opposition-to-alcon-acquisition https://www.market-scope.com/pages/news/8679/klotho-agrees-to-acquire-turn-bio-s-technology-designed-to-restore-cell-function https://www.market-scope.com/pages/news/8664/staar-s-largest-shareholder-to-vote-against-alcon-acquisition-1 https://www.market-scope.com/pages/news/8645/staar-s-largest-shareholder-to-vote-against-alcon-acquisition https://www.market-scope.com/pages/news/8667/sandoz-deal-with-regeneron-will-bring-enzeevu-to-market-in-us-by-q4-2026 https://www.market-scope.com/pages/news/8644/kwangdong-licenses-ocugen-s-rp-gene-therapy-candidate-for-korea https://www.market-scope.com/pages/news/8637/vivani-sets-date-for-spin-off-of-cortigent-subsidiary-formerly-second-sight https://www.market-scope.com/pages/news/8643/sandoz-deal-with-regeneron-will-bring-enzeevu-to-market-in-us-no-later-than-q4-2026 https://www.market-scope.com/pages/news/8602/boehringer-ingelheim-palatin-to-collaborate-on-melanocortin-agonist-for-retina https://www.market-scope.com/pages/news/8639/formycon-klinge-license-eylea-biosimilar-to-horus-for-france-other-european-countries https://www.market-scope.com/pages/news/8625/euroeyes-acquires-seven-betterview-clinics-in-switzerland-plus-uk-assets https://www.market-scope.com/pages/news/8579/alcon-s-acquisition-of-staar-comes-amid-expansion-of-lens-based-refractive-surgery https://www.market-scope.com/pages/news/8556/boehringer-ingelheim-and-re-vana-sign-potential-1-billion-collaboration-deal https://www.market-scope.com/pages/news/8587/boehringer-ingelheim-and-re-vana-sign-potential-1-billion-collaboration-deal-1 https://www.market-scope.com/pages/news/8553/innovia-medical-acquires-ophthalmic-surgical-instrument-maker-hurricane-medical https://www.market-scope.com/pages/news/8560/alcon-agrees-to-acquire-staar-surgical-in-deal-worth-1-5-billion https://www.market-scope.com/pages/news/8552/glaukos-acquires-mobius-therapeutics-and-its-mitosol-antifibrotic-agent https://www.market-scope.com/pages/news/8543/bioeq-licenses-lucentis-biosimilar-to-bio-usawa-for-sub-saharan-africa https://www.market-scope.com/pages/news/8524/alcon-to-acquire-lumithera-and-its-photobiomodulation-device-for-dry-amd-1 https://www.market-scope.com/pages/news/8539/beacon-licenses-abeona-s-aav204-capsid-for-select-ophthalmic-indications https://www.market-scope.com/pages/news/8521/ophthalmic-venture-capital-continues-to-bounce-back-driven-by-retinal-pharma https://www.market-scope.com/pages/news/8531/harrow-secures-us-rights-to-retinal-biosimilars-byooviz-and-opuviz-1 https://www.market-scope.com/pages/news/8511/harrow-secures-us-rights-to-retinal-biosimilars-byooviz-and-opuviz https://www.market-scope.com/pages/news/8508/kowa-licenses-nicox-glaucoma-drop-for-us-other-territories-in-222-million-deal https://www.market-scope.com/pages/news/8494/lenz-licenses-presbyopia-drop-candidate-to-thea-for-canada-in-70-million-deal https://www.market-scope.com/pages/news/8489/hoya-vision-care-acquires-canada-s-centennial-optical https://www.market-scope.com/pages/news/8413/dyno-launches-new-capsid-for-ophthalmic-gene-therapy-developers https://www.market-scope.com/pages/news/8445/ascension-agrees-to-buy-amsurg-s-network-of-ascs https://www.market-scope.com/pages/news/8412/regeneron-buys-23andme-says-move-will-strengthen-its-genetics-guided-drug-development https://www.market-scope.com/pages/news/8429/23andme-seeks-new-bids-after-305-million-offer-from-its-co-founder https://www.market-scope.com/pages/news/8396/elanco-sells-us-royalty-and-milestone-rights-for-xdemvy-to-blackstone-for-295-million-1 https://www.market-scope.com/pages/news/8408/regenxbio-moves-to-monetize-future-royalties-in-deal-worth-up-to-250-million https://www.market-scope.com/pages/news/8369/lenz-licenses-presbyopia-drop-candidate-to-lotus-pharmaceutical-for-korea-southeast-asia https://www.market-scope.com/pages/news/8362/elanco-sells-us-royalty-and-milestone-rights-for-xdemvy-to-blackstone-for-295-million https://www.market-scope.com/pages/news/8381/cambridge-innovation-institute-absorbs-healthegy-s-ois-ois-retina-conferences-1 https://www.market-scope.com/pages/news/8338/microsurgical-technology-to-distribute-mani-s-ophthalmic-blade-portfolio-in-us https://www.market-scope.com/pages/news/8313/biocon-s-deal-with-regeneron-will-bring-yesafili-to-market-in-us-no-later-than-h2-2026 https://www.market-scope.com/pages/news/8314/ophthalmic-venture-capital-funding-hits-a-seven-quarter-peak https://www.market-scope.com/pages/news/8269/us-fda-expands-label-for-iluvien-to-include-chronic-non-infectious-posterior-uveitis https://www.market-scope.com/pages/news/8334/atsena-leads-latest-ophthalmic-fundraising-with-150-million-in-series-c https://www.market-scope.com/pages/news/8267/xbrane-to-sell-part-of-company-to-alvotech-plans-to-keep-ximluci https://www.market-scope.com/pages/news/8266/vivani-now-intends-to-spin-out-cortigent-developer-of-orion-implant https://www.market-scope.com/pages/news/8271/eyenovia-weighs-potential-all-stock-reverse-merger-with-betaliq https://www.market-scope.com/pages/news/8200/novabay-gains-shareholder-approval-to-sell-eye-care-business-1 https://www.market-scope.com/pages/news/8264/cipla-to-market-clobetasol-drops-in-11-countries-including-india-under-license-with-formosa https://www.market-scope.com/pages/news/8180/acelyrin-to-merge-with-alumis-in-all-stock-transaction https://www.market-scope.com/pages/news/8176/bausch-and-lomb-rules-out-sale-after-concluding-bid-process https://www.market-scope.com/pages/news/8190/bausch-and-lomb-rules-out-sale-after-concluding-bid-process-1 https://www.market-scope.com/pages/news/8194/harrow-cencora-partner-to-improve-drug-access-for-retina-specialists-patients-1 https://www.market-scope.com/pages/news/8171/harrow-cencora-partner-to-improve-drug-access-for-retina-specialists-patients https://www.market-scope.com/pages/news/8163/novabay-gains-shareholder-approval-to-sell-eye-care-business https://www.market-scope.com/pages/news/8134/ophthalmology-sees-6-3-billion-in-total-investment-in-2024-with-18-manda-transactions https://www.market-scope.com/pages/news/8151/2024-in-review-alcon-expands-its-glaucoma-portfolio-with-belkin-acquisition https://www.market-scope.com/pages/news/8128/bausch-and-lomb-moves-to-acquire-whitecap-inflammx-to-expand-clinical-pipeline https://www.market-scope.com/pages/news/8124/bausch-and-lomb-to-collaborate-with-character-bio-city-therapeutics-in-amd-ga https://www.market-scope.com/pages/news/8122/teva-signs-deal-to-commercialize-formycon-s-aflibercept-biosimilar-candidate-in-israel-and-most-of-europe https://www.market-scope.com/pages/news/8078/bausch-and-lomb-acquires-elios-vision-developer-of-excimer-laser-trabeculostomy-1 https://www.market-scope.com/pages/news/9029/emerging-companies-pursuing-ophthalmic-indications-march-2026 https://www.market-scope.com/pages/news/8096/visus-merges-with-tenpoint-will-advance-brimochol-once-daily-presbyopia-drop-candidate https://www.market-scope.com/pages/news/8982/pdufa-dates-for-ophthalmic-drug-candidates-february-2026 https://www.market-scope.com/pages/news/8974/emerging-companies-pursuing-ophthalmic-indications-february-2026 https://www.market-scope.com/pages/news/8932/new-rx-drugs-reshape-the-dry-eye-pharma-market https://www.market-scope.com/pages/news/allergy https://www.market-scope.com/pages/news/8835/new-products-power-revenue-growth-in-dry-eye-pharmaceuticals https://www.market-scope.com/pages/news/8918/pdufa-dates-for-ophthalmic-drug-candidates-january-2026 https://www.market-scope.com/pages/news/8916/us-fda-extends-action-date-on-aldeyra-s-reproxalap-to-march-2026-1 https://www.market-scope.com/pages/news/8796/aavantgarde-leads-latest-ophthalmic-fundraising-with-141-million-in-series-b https://www.market-scope.com/pages/news/8683/harrow-to-expand-access-for-all-program-to-full-drug-portfolio https://www.market-scope.com/pages/news/8713/pdufa-dates-for-ophthalmic-drug-candidates-october-2025 https://www.market-scope.com/pages/news/8794/pdufa-dates-for-ophthalmic-drug-candidates-2 https://www.market-scope.com/pages/news/8631/mina-massaro-giordano-md-to-lead-new-dry-eye-service-at-nyu-langone https://www.market-scope.com/pages/news/8555/alcon-launches-tryptyr-acoltremon-drops-for-dry-eye-in-us https://www.market-scope.com/pages/news/8500/rain-eye-drops-launches-dispensing-tool-for-single-use-vials-to-its-customers https://www.market-scope.com/pages/news/8447/dews-iii-report-updates-guidelines-for-diagnosis-management-of-dry-eye https://www.market-scope.com/pages/news/8567/q2-2025-ophthalmic-revenue-roundup-for-regeneron-amgen-abbvie-hoya-and-ocular-therapeutix https://www.market-scope.com/pages/news/8433/bausch-and-lomb-launches-blink-nourish-and-blink-boost-otc-eye-drops-in-us https://www.market-scope.com/pages/news/8442/aldeyra-resubmits-nda-to-us-fda-for-reproxalap-in-dry-eye https://www.market-scope.com/pages/news/8466/us-fda-approves-alcon-s-tryptyr-acoltremon-drops-for-dry-eye-1 https://www.market-scope.com/pages/news/8426/us-fda-approves-alcon-s-tryptyr-acoltremon-drops-for-dry-eye https://www.market-scope.com/pages/news/8373/nearly-76-thousand-cases-of-ocular-lubricants-recalled-us-fda-alert-says https://www.market-scope.com/pages/news/8394/nearly-76-thousand-cases-of-ocular-lubricants-recalled-us-fda-alert-says-1 https://www.market-scope.com/pages/news/8349/csi-dry-eye-software-appoints-ken-barbet-as-ceo https://www.market-scope.com/pages/news/8324/job-and-funding-cuts-in-us-hhs-department-hit-ophthalmic-community https://www.market-scope.com/pages/news/8320/us-fda-again-rejects-aldeyra-s-reproxalap-for-dry-eye-asks-for-yet-another-symptom-trial-1 https://www.market-scope.com/pages/news/8295/nordic-pharma-secures-ce-marking-for-lacrifill-canalicular-gel-in-dry-eye https://www.market-scope.com/pages/news/8327/nordic-pharma-secures-ce-marking-for-lacrifill-canalicular-gel-in-dry-eye-1 https://www.market-scope.com/pages/news/8288/2024-ophthalmic-revenue-roundup-for-harrow-astellas-iridex-and-xbrane https://www.market-scope.com/pages/news/8287/us-fda-again-rejects-aldeyra-s-reproxalap-for-dry-eye-asks-for-yet-another-symptom-trial https://www.market-scope.com/pages/news/8211/bausch-and-lomb-posts-2024-revenue-of-4-8-billion https://www.market-scope.com/pages/news/8227/mediprint-ophthalmics-adds-ha-eluting-contact-lens-to-pipeline https://www.market-scope.com/pages/news/8219/alcon-launches-systane-pro-preservative-free-drops-for-dry-eye-in-us https://www.market-scope.com/pages/news/8154/senju-files-for-marketing-approval-of-dry-eye-candidate-sjp-0132-in-japan https://www.market-scope.com/pages/news/8174/2024-ophthalmic-revenue-roundup-for-roche-abbvie-novartis https://www.market-scope.com/pages/news/8125/tarsus-will-advance-lotilaner-eyelid-gel-for-ocular-rosacea https://www.market-scope.com/pages/news/8105/alcon-recalls-single-lot-of-systane-ultra-pf-drops-over-fungal-contamination https://www.market-scope.com/pages/news/8167/2024-revenue-roundup-for-jandj-vision-lumibird-and-nicox https://www.market-scope.com/pages/news/8062/fall-of-restasis-weighs-on-dry-eye-revenue-in-2024 https://www.market-scope.com/pages/news/8086/pdufa-dates-for-ophthalmic-drug-candidates https://www.market-scope.com/pages/news/8064/weekly-surgeon-poll-december-2024 https://www.market-scope.com/pages/news/8063/december-2024-ophthalmic-news-briefs https://www.market-scope.com/pages/news/8084/select-us-fda-approvals-and-clearances-in-november-2024 https://www.market-scope.com/pages/news/8915/2025-in-review-sydnexis-atropine-drop-for-myopia-rejected-in-us-approved-elsewhere https://www.market-scope.com/pages/news/8733/2025-escrs-congress-boasts-strong-attendance-and-multiple-product-launches https://www.market-scope.com/pages/news/8718/attendees-in-copenhagen-debate-whether-lasers-will-replace-migs-stents https://www.market-scope.com/pages/news/8732/escrs-roundtable-grapples-with-impact-of-cataract-surgery-waste https://www.market-scope.com/pages/news/8638/alteogen-gains-eu-approval-for-eylea-biosimilar-eyluxvi https://www.market-scope.com/pages/news/8716/escrs-celebrates-30-years-of-femtosecond-lasers-in-ophthalmology https://www.market-scope.com/pages/news/8656/ciliatech-s-intercil-uveal-spacer-for-glaucoma-gains-ce-marking-already-cleared-in-uk https://www.market-scope.com/pages/news/8623/roche-gains-ce-marking-for-port-delivery-platform-branded-contivue-in-europe https://www.market-scope.com/pages/news/8632/nanoscope-s-mco-010-gains-five-ema-orphan-designations-and-us-fda-rmat-status https://www.market-scope.com/pages/news/8627/ema-grants-orphan-status-for-aldeyra-s-methotrexate-formulation-in-prvl https://www.market-scope.com/pages/news/8613/ciliatech-s-intercil-uveal-spacer-for-glaucoma-gains-ce-marking https://www.market-scope.com/pages/news/8606/alvotech-advanz-gain-eu-approval-for-eylea-biosimilar-under-brand-name-mynzepli https://www.market-scope.com/pages/news/8591/santen-launches-ryjunea-drops-in-germany-for-pediatric-myopia-1 https://www.market-scope.com/pages/news/8551/aflibercept-biosimilar-candidate-from-alteogen-gains-positive-chmp-opinion https://www.market-scope.com/pages/news/8573/ema-selects-annexon-s-ga-candidate-for-regulatory-pilot-program https://www.market-scope.com/pages/news/8562/ema-grants-orphan-designation-to-aldeyra-s-methotrexate-injection-for-rp https://www.market-scope.com/pages/news/8498/eu-regulators-approve-extended-six-month-treatment-interval-for-eylea-8-mg https://www.market-scope.com/pages/news/8478/glaukos-gains-eu-mdr-certification-of-devices-in-istent-platform https://www.market-scope.com/pages/news/8547/santen-launches-ryjunea-drops-in-germany-for-pediatric-myopia https://www.market-scope.com/pages/news/8497/aflibercept-biosimilar-candidate-from-alvotech-gains-positive-chmp-opinion https://www.market-scope.com/pages/news/8454/sydnexis-gains-eu-approval-for-low-dose-atropine-drops-in-pediatric-myopia-1 https://www.market-scope.com/pages/news/8480/scottish-regulators-endorse-outlook-s-lytenava-for-nhs-scotland-use-in-wet-amd https://www.market-scope.com/pages/news/8461/talks-on-pharma-reforms-cloud-future-of-europe-s-health-care-market https://www.market-scope.com/pages/news/8388/bausch-and-lomb-receives-ce-marking-for-preloaded-luxlife-trifocal-iol-1 https://www.market-scope.com/pages/news/8434/sydnexis-gains-eu-approval-for-low-dose-atropine-drops-in-pediatric-myopia https://www.market-scope.com/pages/news/8432/outlook-launches-lytenava-bevacizumab-in-germany-uk-for-wet-amd https://www.market-scope.com/pages/news/8303/sanoculis-receives-ce-marking-for-mint-procedure-for-glaucoma https://www.market-scope.com/pages/news/8336/may-12-is-deadline-to-apply-for-ramin-tadayoni-award-for-research https://www.market-scope.com/pages/news/8284/sydnexis-receives-positive-chmp-opinion-for-low-dose-atropine-drops-in-pediatric-myopia https://www.market-scope.com/pages/news/8209/celltrion-gains-eu-approval-for-aflibercept-biosimilar-branded-eydenzelt https://www.market-scope.com/pages/news/8222/ocugen-s-gene-therapy-candidates-for-ga-and-stargardt-gain-advanced-therapy-status-in-europe https://www.market-scope.com/pages/news/8156/formycon-klinge-gain-eu-approval-for-eylea-biosimilar-under-brand-names-ahzantive-and-baiama https://www.market-scope.com/pages/news/8178/ocugen-s-rp-gene-therapy-candidate-gains-advanced-therapy-status-in-europe https://www.market-scope.com/pages/news/8142/2024-in-review-complement-therapies-for-ga-fall-short-in-bid-for-approval-in-eu https://www.market-scope.com/pages/news/8169/aflibercept-biosimilar-candidate-from-amgen-gains-positive-chmp-opinion https://www.market-scope.com/pages/news/8123/bausch-and-lomb-launches-envista-aspire-monofocal-plus-iols-in-europe https://www.market-scope.com/pages/news/8093/aflibercept-biosimilar-candidate-from-celltrion-gains-positive-chmp-opinion https://www.market-scope.com/pages/news/8102/roche-s-vabysmo-prefilled-syringe-approved-in-eu-for-wet-amd-dme-and-rvo https://www.market-scope.com/pages/news/8720/nonexudative-retinal-pharmaceuticals-market-seeing-early-signs-of-diversification https://www.market-scope.com/pages/news/8070/samsung-bioepis-biogen-gain-eu-approval-for-aflibercept-biosimilar-known-as-opuviz-1 https://www.market-scope.com/pages/news/8779/fda-clears-way-for-us-patient-to-receive-gensight-s-lumevoq-for-lhon-1 https://www.market-scope.com/pages/news/8626/4dmt-promotes-julie-clark-md-to-chief-medical-officer https://www.market-scope.com/pages/news/8672/nei-awards-u-of-houston-researchers-3-6-million-to-investigate-vision-critical-gene https://www.market-scope.com/pages/news/8670/us-fda-grants-fast-track-status-to-sanofi-s-wet-amd-gene-therapy-candidate https://www.market-scope.com/pages/news/8607/us-fda-grants-rmat-status-to-veongen-s-gene-therapy-candidate-in-stargardt https://www.market-scope.com/pages/news/8569/us-fda-grants-fast-track-status-to-aavantgarde-s-stargardt-candidate https://www.market-scope.com/pages/news/8592/ocugen-leads-latest-ophthalmic-fundraising-with-20-million-offering https://www.market-scope.com/pages/news/8538/us-fda-grants-fast-track-status-to-sanofi-s-ga-gene-therapy-candidate https://www.market-scope.com/pages/news/8507/nanoscope-initiates-rolling-bla-submission-for-optogenetic-rp-candidate https://www.market-scope.com/pages/news/8487/children-s-hospital-los-angeles-receives-12m-gift-to-expand-cell-gene-therapies https://www.market-scope.com/pages/news/8460/innovation-and-collaboration-take-center-stage-at-eyecelerator-meeting https://www.market-scope.com/pages/news/8435/vigeneron-rebrands-as-veongen-gains-rare-pediatric-nod-for-stargardt-candidate https://www.market-scope.com/pages/news/8436/beacon-therapeutics-appoints-daniel-chung-do-as-chief-medical-officer https://www.market-scope.com/pages/news/8417/us-fda-grants-rare-pediatric-designation-to-ocugen-s-gene-therapy-candidate-for-stargardt https://www.market-scope.com/pages/news/8357/us-fda-grants-rmat-status-to-opus-lca5-gene-therapy-candidate https://www.market-scope.com/pages/news/8230/us-fda-grants-fast-track-status-to-atsena-s-x-linked-retinoschisis-gene-therapy-candidate https://www.market-scope.com/pages/news/8356/us-fda-grants-rmat-status-to-4dmt-s-gene-therapy-candidate-in-dme https://www.market-scope.com/pages/news/8297/us-fda-grants-rmat-status-to-atsena-s-x-linked-retinoschisis-gene-therapy-candidate https://www.market-scope.com/pages/news/8188/study-shows-promise-for-genetic-base-editing-in-stargardt-disease-1 https://www.market-scope.com/pages/news/8224/avirmax-initiates-ind-enabling-studies-of-dry-amd-triple-gene-therapy-candidate https://www.market-scope.com/pages/news/8187/emerging-companies-pursuing-ophthalmic-indications-5 https://www.market-scope.com/pages/news/8208/us-fda-grants-rmat-designation-for-bionic-sight-s-rp-gene-therapy-candidate https://www.market-scope.com/pages/news/8135/children-s-hospital-los-angeles-celebrates-100th-luxturna-procedure-1 https://www.market-scope.com/pages/news/8161/us-fda-grants-rare-pediatric-designation-to-meiragtx-lca1-gene-therapy-candidate https://www.market-scope.com/pages/news/8179/us-fda-grants-rmat-designation-for-beacon-s-xlrp-gene-therapy-candidate https://www.market-scope.com/pages/news/8108/us-fda-grants-rare-pediatric-disease-designation-to-eyedna-s-rp-gene-therapy-candidate https://www.market-scope.com/pages/news/8109/children-s-hospital-los-angeles-celebrates-100th-luxturna-procedure https://www.market-scope.com/pages/news/8126/study-shows-promise-for-genetic-base-editing-in-stargardt-disease https://www.market-scope.com/pages/news/8971/g360-meeting-sets-fundraising-record-shines-spotlight-on-range-of-stakeholders https://www.market-scope.com/pages/news/8976/us-fda-approves-re-administration-of-glaukos-idose-tr-1 https://www.market-scope.com/pages/news/8989/market-scope-s-g360-attendee-survey-looks-at-patient-fears-over-laser-therapy https://www.market-scope.com/pages/news/migs https://www.market-scope.com/pages/news/8924/meet-with-market-scope-at-the-2026-glaucoma-360-meeting https://www.market-scope.com/pages/news/8902/weekly-poll-of-mds-us-and-western-europe-january-2026 https://www.market-scope.com/pages/news/8829/ophthalmologists-report-2-6-percent-decrease-in-q3-2025-procedure-volume https://www.market-scope.com/pages/news/8839/bausch-and-lomb-outlines-growth-plans-driven-by-deep-pipeline-1 https://www.market-scope.com/pages/news/8791/aao-speakers-continue-to-promote-glaucoma-laser-innovation-and-effectiveness https://www.market-scope.com/pages/news/8724/iantrek-announces-us-commercial-launch-of-alloflo-uveo-biostent https://www.market-scope.com/pages/news/8671/amneal-gains-us-fda-approval-for-generic-bimatoprost-0-01-eye-drop https://www.market-scope.com/pages/news/8652/ophthalmic-company-revenue-down-1-9-percent-in-q2-2025-as-multiple-firms-report-declines https://www.market-scope.com/pages/news/8654/new-world-medical-launches-clearpath-st-with-smaller-tube-lumen-1 https://www.market-scope.com/pages/news/8628/new-world-medical-launches-clearpath-st-with-smaller-tube-lumen https://www.market-scope.com/pages/news/8619/santen-gains-approval-in-japan-for-setaneo-sepetaprost-glaucoma-drops https://www.market-scope.com/pages/news/8609/glaucoma-research-foundation-to-use-5-million-gift-to-create-accelerator https://www.market-scope.com/pages/news/8585/novel-subconjunctival-devices-expected-to-improve-treatment-for-more-advanced-glaucoma-patients https://www.market-scope.com/pages/news/8578/weekly-surgeon-poll-august-2025 https://www.market-scope.com/pages/news/8570/first-commercial-procedure-performed-with-bvi-s-laser-endoscopy-system-for-glaucoma https://www.market-scope.com/pages/news/8554/new-minnesota-law-expands-ods-authority-to-prescribe-drugs-perform-injections https://www.market-scope.com/pages/news/8536/glaucoma-laser-company-vialase-appoints-shawn-o-neil-as-ceo https://www.market-scope.com/pages/news/8481/polyactiva-names-new-ceo-raises-25-million-to-advance-sustained-release-glaucoma-implant https://www.market-scope.com/pages/news/8451/ophthalmologists-report-3-percent-decrease-in-q1-2025-procedure-volume https://www.market-scope.com/pages/news/8456/new-world-medical-launches-new-streamline-with-transparent-tip-1 https://www.market-scope.com/pages/news/8438/qlaris-bio-will-advance-fixed-dose-combo-therapy-for-glaucoma-with-qls-111-and-latanoprost https://www.market-scope.com/pages/news/8407/new-world-medical-launches-new-streamline-with-transparent-tip https://www.market-scope.com/pages/news/8380/competition-from-generics-strong-dollar-shape-the-global-glaucoma-pharma-market https://www.market-scope.com/pages/news/8403/surgeon-at-alcon-presentation-looks-at-voyager-dslt-s-role-in-changing-treatment-landscape https://www.market-scope.com/pages/news/8365/tme-pharma-to-expand-cost-cutting-nominate-new-ceo https://www.market-scope.com/pages/news/8353/new-laws-in-montana-west-virginia-expand-ods-scope-to-include-laser https://www.market-scope.com/pages/news/8304/us-fda-grants-510-k-clearance-to-bvi-s-laser-endoscopy-system-for-glaucoma https://www.market-scope.com/pages/news/8238/ags-meeting-features-technology-updates-voyager-dslt-launch https://www.market-scope.com/pages/news/8248/ophthalmologists-report-5-3-percent-increase-in-q4-2024-procedure-volume https://www.market-scope.com/pages/news/8333/indian-glaucoma-surgeons-embrace-migs-procedures-over-devices https://www.market-scope.com/pages/news/8260/select-us-fda-approvals-and-clearances-in-february-2025 https://www.market-scope.com/pages/news/8242/new-world-medical-gains-us-clearance-for-the-via360-viscodilation-system-for-glaucoma https://www.market-scope.com/pages/news/8212/new-world-medical-gains-us-510-k-clearance-for-the-via360-viscodilation-system-for-glaucoma https://www.market-scope.com/pages/news/8210/alcon-announces-us-launch-of-voyager-dslt-for-glaucoma https://www.market-scope.com/pages/news/8185/g360-s-new-horizons-forum-highlights-innovations-and-discusses-the-future-of-glaucoma-therapy https://www.market-scope.com/pages/news/8193/norlase-strengthens-position-in-ophthalmic-laser-market-with-launch-of-lynx-lio https://www.market-scope.com/pages/news/8199/market-scope-and-the-glaucoma-research-foundation-celebrate-10-years-of-partnership https://www.market-scope.com/pages/news/8170/iantrek-appoints-adam-szaronos-as-chief-executive-officer https://www.market-scope.com/pages/news/8152/2024-in-review-mac-turmoil-shakes-out-with-final-policy-on-coverage-of-migs https://www.market-scope.com/pages/news/8094/nurexone-reports-promising-preclinical-results-in-restoring-vision-after-optic-nerve-damage https://www.market-scope.com/pages/news/8092/vialase-teams-up-with-moran-eye-center-to-enhance-femto-laser-glaucoma-procedure https://www.market-scope.com/pages/news/8074/ophthalmologists-report-5-5-percent-increase-in-q3-2024-procedure-volume https://www.market-scope.com/pages/news/8071/macs-finalize-coverage-for-standalone-and-combo-migs-procedures-1 https://www.market-scope.com/pages/news/8061/bausch-and-lomb-acquires-elios-vision-developer-of-excimer-laser-trabeculostomy https://www.market-scope.com/pages/news/8427/gore-launches-silicone-free-plunger-for-ophthalmic-prefilled-syringes https://www.market-scope.com/pages/news/8798/mallinckrodt-spins-off-generics-business-rebrands-as-keenova-1 https://www.market-scope.com/pages/news/8979/staar-names-warren-foust-and-deborah-andrews-as-interim-co-ceos-amid-search-for-permanent-leader-1 https://www.market-scope.com/pages/news/8635/eyexora-cofounded-by-bill-link-launches-at-futures-forum https://www.market-scope.com/pages/news/8734/valitor-appoints-gregory-d-kunst-as-chief-executive-officer https://www.market-scope.com/pages/news/8686/harrow-names-frank-mullery-as-ceo-of-imprimisrx-subsidiary https://www.market-scope.com/pages/news/8537/outlook-therapeutics-appoints-bob-jahr-as-ceo https://www.market-scope.com/pages/news/8509/clearside-explores-strategic-alternatives-transitions-workforce https://www.market-scope.com/pages/news/8548/unity-board-dissolves-company-ending-research-targeting-senescent-cells https://www.market-scope.com/pages/news/8528/clearside-explores-strategic-alternatives-transitions-workforce-1 https://www.market-scope.com/pages/news/8393/new-sightline-meeting-focuses-on-business-acumen-within-industry https://www.market-scope.com/pages/news/8444/regeneron-declines-to-submit-new-bid-for-23andme-after-higher-offer-from-co-founder https://www.market-scope.com/pages/news/8351/nanodrops-names-daria-lemann-blumenthal-as-ceo https://www.market-scope.com/pages/news/8409/two-ai-driven-drug-discovery-firms-win-2025-astellas-future-innovator-prize https://www.market-scope.com/pages/news/8301/cambridge-innovation-institute-absorbs-healthegy-s-ois-ois-retina-conferences https://www.market-scope.com/pages/news/8330/retina-pharma-and-premium-iols-continue-to-drive-ophthalmic-market https://www.market-scope.com/pages/news/8350/allotex-ramps-up-commercialization-of-presbyopia-implant-appoints-michael-mrochen-phd-as-ceo https://www.market-scope.com/pages/news/8263/astellas-mbc-biolabs-offer-sixth-future-innovator-prize https://www.market-scope.com/pages/news/8243/ophthalmic-company-revenue-up-5-1-percent-as-four-firms-report-record-high-quarters https://www.market-scope.com/pages/news/8281/aviceda-appoints-jeffrey-nau-phd-mms-as-chief-executive-officer https://www.market-scope.com/pages/news/prosthesis https://www.market-scope.com/pages/news/8218/staar-appoints-stephen-c-farrell-as-president-ceo-tom-frinzi-to-remain-as-adviser-through-january-2026 https://www.market-scope.com/pages/news/8311/thomas-panek-becomes-president-ceo-of-lighthouse-guild https://www.market-scope.com/pages/news/8115/unity-biotechnology-appoints-federico-grossi-md-phd-as-chief-medical-officer https://www.market-scope.com/pages/news/9030/new-law-in-kansas-expands-ods-scope-to-include-laser-1 https://www.market-scope.com/pages/news/8792/select-us-fda-approvals-and-clearances-in-october-2025 https://www.market-scope.com/pages/news/8268/thomas-panek-to-lead-lighthouse-guild https://www.market-scope.com/pages/news/8065/asia-pacific-markets-and-lens-based-procedures-drive-refractive-surgery https://www.market-scope.com/pages/news/8149/2024-in-review-smile-for-hyperopia-two-excimer-lasers-lead-refractive-surgical-news https://www.market-scope.com/pages/news/8166/norlase-receives-us-clearance-and-ce-marking-for-lynx-pattern-scanning-laser-indirect-ophthalmoscope https://www.market-scope.com/pages/news/9036/moderates-and-radicals-in-myopia-tussle-at-apao-congress-over-treatment-goals https://www.market-scope.com/pages/news/9037/root-cause-of-myopia-still-eludes-researchers-apao-congress-reveals https://www.market-scope.com/pages/news/8060/zeiss-gains-us-approval-for-mel-90-excimer-laser https://www.market-scope.com/pages/news/8988/new-us-law-institutes-major-pharmacy-benefit-manager-reforms-in-2029-1 https://www.market-scope.com/pages/news/8972/weekly-poll-of-mds-and-ods-february-2026 https://www.market-scope.com/pages/news/8983/us-fda-approves-tenpoint-s-yuvezzi-drops-for-presbyopia-1 https://www.market-scope.com/pages/news/8923/2025-in-review-turmoil-reigns-at-us-fda-with-leadership-shuffling-and-high-level-exits https://www.market-scope.com/pages/news/8970/aoa-sounds-alert-on-eyebot-vision-kiosks-calls-for-greater-oversight-1 https://www.market-scope.com/pages/news/8917/2025-in-review-us-refractive-surgery-volumes-hit-record-low-amid-economic-funk https://www.market-scope.com/pages/news/8913/us-fda-rejects-outlook-s-lytenava-for-a-third-time-citing-lack-of-efficacy https://www.market-scope.com/pages/news/8909/2025-in-review-encelto-for-mactel-nabs-many-firsts-opens-new-area-of-study https://www.market-scope.com/pages/news/8907/virtual-retina-could-help-unlock-new-treatments-for-vision-loss https://www.market-scope.com/pages/news/8850/duke-becomes-first-academic-center-to-implant-encelto https://www.market-scope.com/pages/news/8846/us-fda-approves-eylea-hd-for-rvo-plus-monthly-dosing-in-all-approved-indications-1 https://www.market-scope.com/pages/news/8851/pdufa-dates-for-ophthalmic-drug-candidates-december-2025 https://www.market-scope.com/pages/news/8844/mit-research-offers-new-treatment-approach-for-amblyopia https://www.market-scope.com/pages/news/8837/finland-researchers-study-heat-s-role-in-slowing-progression-of-dry-amd https://www.market-scope.com/pages/news/8833/weekly-poll-of-us-mds-and-ods-december-2025 https://www.market-scope.com/pages/news/8836/cder-chief-pazdur-retiring-from-us-fda-makary-names-hoeg-as-replacement-1 https://www.market-scope.com/pages/news/8793/interest-builds-for-presbyopia-drops-as-third-therapy-hits-market https://www.market-scope.com/pages/news/8777/aao-retina-sessions-delve-into-wide-field-imaging-diabetic-eye-disease-and-more https://www.market-scope.com/pages/news/8780/medicare-updates-offer-mixed-bag-for-eye-doctors-aao-policy-experts-say https://www.market-scope.com/pages/news/8781/uk-high-court-ruling-paves-way-for-launch-of-alvotech-s-aflibercept-biosimilar-1 https://www.market-scope.com/pages/news/8785/us-fda-rejects-sydnexis-low-dose-atropine-drop-for-pediatric-myopia https://www.market-scope.com/pages/news/8784/richard-pazdur-md-to-lead-us-fda-s-center-for-drug-evaluation-and-research-1 https://www.market-scope.com/pages/news/8709/weekly-surgeon-poll-october-2025 https://www.market-scope.com/pages/news/8731/eylea-biosimilars-pushing-at-market-gates-could-disrupt-pricing https://www.market-scope.com/pages/news/8712/myopia-lenses-from-essilorluxottica-gain-us-fda-de-novo-marketing-authorization-1 https://www.market-scope.com/pages/news/8647/annexon-aims-to-make-difference-in-ga-by-focusing-on-neuroprotection https://www.market-scope.com/pages/news/8646/alcon-and-bvi-launch-new-vitrectomy-systems-at-euretina-congress-in-paris https://www.market-scope.com/pages/news/8661/fda-looks-to-end-advisory-panel-meetings https://www.market-scope.com/pages/news/8658/regulatory-panel-in-japan-recommends-izervay-for-approval-in-ga-1 https://www.market-scope.com/pages/news/8662/us-fda-again-rejects-outlook-s-lytenava-for-wet-amd-citing-lack-of-efficacy-evidence-1 https://www.market-scope.com/pages/news/8577/asrs-meeting-returns-surgery-to-the-forefront-of-discussion https://www.market-scope.com/pages/news/8653/moran-celebrates-approval-of-ai-tech-to-help-time-injections-for-wet-amd-1 https://www.market-scope.com/pages/news/8649/weekly-surgeon-poll-september-2025 https://www.market-scope.com/pages/news/8588/us-fda-approves-lenz-vizz-aceclidine-drops-for-presbyopia-1 https://www.market-scope.com/pages/news/8582/nanoscope-targets-sight-restoration-instead-of-blindness-prevention https://www.market-scope.com/pages/news/8590/us-cms-issues-j-code-for-encelto-q-code-for-yesafili-for-billing-payers-1 https://www.market-scope.com/pages/news/8594/new-hhs-plan-adds-prior-authorization-to-medicare https://www.market-scope.com/pages/news/8599/methotrexate-has-avastin-moment-at-asrs-meeting https://www.market-scope.com/pages/news/8586/new-minnesota-law-expands-ods-authority-for-drugs-injections https://www.market-scope.com/pages/news/8581/eye-physicians-researchers-band-together-to-stave-off-nei-cuts https://www.market-scope.com/pages/news/8598/asrs-sessions-highlight-value-of-amniotic-membrane-in-retinal-surgery https://www.market-scope.com/pages/news/8512/octane-examines-changing-refractive-surgery-landscape https://www.market-scope.com/pages/news/8596/speakers-at-asrs-meeting-lament-dwindling-access-to-operating-room https://www.market-scope.com/pages/news/scope-of-practice https://www.market-scope.com/pages/news/8611/eyebot-to-expand-self-serve-vision-testing-kiosks-with-20-million-financing https://www.market-scope.com/pages/news/8250/new-arkansas-law-reins-in-vision-care-insurers-influence-over-ods https://www.market-scope.com/pages/news/ascrs https://www.market-scope.com/pages/news/escrs https://www.market-scope.com/pages/news/aao https://www.market-scope.com/pages/news/eyecelerator https://www.market-scope.com/pages/news/8603/philippine-academy-of-ophthalmology-warns-of-fake-website-for-congress https://www.market-scope.com/pages/news/8459/arvo-sets-tone-for-ai-focused-week-with-avatar-at-keynote-speech https://www.market-scope.com/pages/news/8470/arvo-showcases-manufacturers-looking-to-refine-ocular-injections https://www.market-scope.com/pages/news/8398/humanitarian-outreach-front-and-center-at-2025-ascrs-meeting https://www.market-scope.com/pages/news/8462/eyecelerator-meeting-s-expert-panelists-portray-an-fda-in-flux https://www.market-scope.com/pages/news/8255/meet-with-market-scope-at-the-2025-ascrs-meeting https://www.market-scope.com/pages/news/8397/dr-glaukomflecken-pushes-ascrs-attendees-to-harness-social-media-public-pressure-for-change https://www.market-scope.com/pages/news/8395/ascrs-meeting-draws-more-than-4-600 https://www.market-scope.com/pages/news/8559/us-fda-approves-lenz-vizz-aceclidine-drops-for-presbyopia https://www.market-scope.com/pages/news/8249/arvo-extends-deadline-for-attendees-to-meeting-to-pay-reduced-fees https://www.market-scope.com/pages/news/8533/premium-presbyopia-treatment-rates-remain-low-despite-new-product-launches https://www.market-scope.com/pages/news/8431/us-fda-accepts-tenpoint-s-nda-for-presbyopia-drop-sets-pdufa-date-of-jan-28-2026 https://www.market-scope.com/pages/news/8682/lenz-launches-vizz-drops-for-presbyopia-in-us https://www.market-scope.com/pages/news/8323/orasis-launches-qlosi-presbyopia-drops-in-us-1 https://www.market-scope.com/pages/news/8292/orasis-launches-qlosi-presbyopia-drops-in-us https://www.market-scope.com/pages/news/8213/opus-gains-fda-fast-track-status-for-phentolamine-drops-for-night-driving-impairment https://www.market-scope.com/pages/news/8296/tenpoint-submits-nda-to-us-fda-for-brimochol-pf-in-presbyopia https://www.market-scope.com/pages/news/generics https://www.market-scope.com/pages/news/8146/us-fda-pdufa-dates-for-ophthalmic-drug-candidates https://www.market-scope.com/pages/news/biosimilars https://www.market-scope.com/pages/news/8690/generic-drugmakers-with-us-sources-now-eligible-for-fda-priority-review https://www.market-scope.com/pages/news/8676/us-fda-accepts-idebenone-nda-for-priority-review-sets-pdufa-date-of-feb-28-2026 https://www.market-scope.com/pages/news/8642/fda-drug-official-looks-to-end-advisory-panel-meetings https://www.market-scope.com/pages/news/8681/outlook-meets-with-us-fda-plans-to-resubmit-bla-for-lytenava-this-year https://www.market-scope.com/pages/news/biologic https://www.market-scope.com/pages/news/8620/regulatory-panel-in-japan-recommends-izervay-for-approval-in-ga https://www.market-scope.com/pages/news/8618/us-fda-begins-daily-reporting-of-adverse-event-data https://www.market-scope.com/pages/news/8610/manufacturer-inspection-report-delays-two-eylea-hd-target-action-dates https://www.market-scope.com/pages/news/8541/novartis-reports-q2-2025-lucentis-revenue-of-173-million https://www.market-scope.com/pages/news/8614/us-fda-again-rejects-outlook-s-lytenava-for-wet-amd-citing-lack-of-efficacy-evidence https://www.market-scope.com/pages/news/8477/amneal-gains-us-fda-approval-for-generic-prednisolone-acetate-eye-drop https://www.market-scope.com/pages/news/8471/gore-launches-silicone-free-plunger-for-ophthalmic-prefilled-syringes-1 https://www.market-scope.com/pages/news/8430/fda-begins-listening-tour-with-pharma-ceos-to-improve-regulatory-process https://www.market-scope.com/pages/news/8448/us-fda-aims-to-speed-drug-review-to-under-two-months-with-new-voucher-program https://www.market-scope.com/pages/news/8341/us-fda-rejects-regeneron-s-sbla-for-eylea-hd-dosing-interval-beyond-16-weeks https://www.market-scope.com/pages/news/8410/us-fda-approves-genentech-s-susvimo-refillable-implant-for-dr https://www.market-scope.com/pages/news/8406/us-fda-grants-breakthrough-status-to-belite-bio-s-oral-stargardt-candidate https://www.market-scope.com/pages/news/8236/us-fda-accepts-nda-for-sydnexis-low-dose-atropine-for-myopia-sets-pdufa-date-of-oct-23-2025 https://www.market-scope.com/pages/news/8329/pdufa-dates-for-ophthalmic-drug-candidates-april-2025 https://www.market-scope.com/pages/news/8155/arctic-vision-gains-approval-of-arcatus-xipere-for-uveitic-macular-edema-in-australia-singapore https://www.market-scope.com/pages/news/8294/us-fda-accepts-outlook-s-resubmitted-bla-for-lytenava-sets-pdufa-date-of-aug-27 https://www.market-scope.com/pages/news/8085/us-fda-rejects-snda-for-izervay-seeking-every-other-month-dosing-1 https://www.market-scope.com/pages/news/8183/us-fda-approves-expanded-label-for-izervay-to-extend-treatment-for-ga-beyond-12-months https://www.market-scope.com/pages/news/amblyopia https://www.market-scope.com/pages/news/hyperopia https://www.market-scope.com/pages/news/myopia https://www.market-scope.com/pages/news/8076/zeiss-gains-us-approval-for-next-gen-mel-90-excimer-laser https://www.market-scope.com/pages/news/8469/allotex-launches-refractive-corneal-implant-in-canada-1 https://www.market-scope.com/pages/news/8693/us-senator-to-review-ama-s-fee-structure-to-use-its-cpt-code-set https://www.market-scope.com/pages/news/patent https://www.market-scope.com/pages/news/8640/uk-s-nice-approves-first-treatment-for-leber-hereditary-optic-neuropathy-lhon https://www.market-scope.com/pages/news/8685/myopia-lenses-from-essilorluxottica-gain-us-fda-de-novo-marketing-authorization https://www.market-scope.com/pages/news/8675/regulators-in-japan-approve-aflibercept-eylea-biosimilar-from-alvotech-and-fuji https://www.market-scope.com/pages/news/8565/us-cms-issues-j-code-for-encelto-q-code-for-yesafili-for-billing-payers https://www.market-scope.com/pages/news/8622/hhs-agrees-to-restore-deleted-web-pages-in-lawsuit-settlement https://www.market-scope.com/pages/news/8566/eye-physicians-researchers-band-together-to-stave-off-nei-cuts-consolidation https://www.market-scope.com/pages/news/8608/us-fda-grants-fast-track-status-to-aldeyra-s-adx-2191-methotrexate-for-rp https://www.market-scope.com/pages/news/8527/health-insurers-pledge-to-reform-prior-authorization-by-2026-1 https://www.market-scope.com/pages/news/8542/regulators-in-canada-approve-xipere-for-uveitic-macular-edema https://www.market-scope.com/pages/news/8546/george-tidmarsh-md-phd-named-to-lead-fda-s-center-for-drug-evaluation-and-research https://www.market-scope.com/pages/news/8691/teresa-puthussery-phd-od-named-2025-macarthur-fellow https://www.market-scope.com/pages/news/8550/um-whole-eye-transplant-project-overcomes-two-hurdles https://www.market-scope.com/pages/news/8443/nih-study-determines-brain-circuits-affected-by-retinal-cell-loss https://www.market-scope.com/pages/news/8633/ucla-study-reveals-complex-muscle-control-behind-blinking-and-eyelid-function https://www.market-scope.com/pages/news/8244/early-study-shows-promise-for-head-mounted-retinal-surgery-robot-1 https://www.market-scope.com/pages/news/8191/ophthalmology-officials-doctors-researchers-feel-effects-of-trump-s-sweeping-changes https://www.market-scope.com/pages/news/8232/early-study-shows-promise-for-head-mounted-retinal-surgery-robot https://www.market-scope.com/pages/news/8098/scripps-research-includes-amd-among-its-regenerative-medicine-targets https://www.market-scope.com/pages/news/8099/2-3-million-nih-grant-furthers-u-of-oklahoma-research-into-retinopathy-of-prematurity https://www.market-scope.com/pages/news/8058/arpa-h-pledges-125-million-in-quest-to-advance-whole-eye-transplants https://www.market-scope.com/pages/news/8075/nyu-langone-health-hails-recovery-of-man-over-a-year-after-landmark-whole-eye-transplant https://www.market-scope.com/pages/news/8073/arpa-h-pledges-125-million-to-advance-whole-eye-transplantation https://www.market-scope.com/pages/news/single-use https://www.market-scope.com/pages/news/8616/lambdavision-secures-nasa-award-to-advance-manufacturing-of-artificial-retina-in-low-earth-orbit https://www.market-scope.com/pages/news/8490/ophthalmology-tops-us-specialties-for-percentage-of-doctors-in-private-practice https://www.market-scope.com/pages/news/8368/us-fda-grants-breakthrough-status-to-viridian-s-thyroid-eye-disease-candidate https://www.market-scope.com/pages/news/8571/first-commercial-procedure-performed-with-encelto-only-fda-approved-treatment-for-mactel https://www.market-scope.com/pages/news/8235/2024-ophthalmic-revenue-roundup-for-amgen-and-biogen https://www.market-scope.com/pages/news/8223/japanese-regulators-grant-orphan-drug-status-to-hanall-s-batoclimab-in-active-thyroid-eye-disease https://www.market-scope.com/pages/news/8455/ophthalmic-company-revenue-in-q1-2025-down-2-1-percent-as-multiple-firms-report-declines https://www.market-scope.com/pages/reports/432/ophthalmic-market-trends-us-refractive-edition-q4-2023 https://www.market-scope.com/pages/news/8144/2024-in-review-change-healthcare-and-hoya-data-breaches-highlight-security-risks https://www.market-scope.com/pages/news/8475/regenxbio-leads-latest-ophthalmic-fundraising-with-150-million-royalty-sale https://www.market-scope.com/pages/news/8068/ophthalmic-company-revenue-up-6-3-percent-as-four-companies-report-record-high-quarters https://www.market-scope.com/pages/news/8495/biocon-gains-approval-in-canada-for-yesafili-a-biosimilar-to-eylea https://www.market-scope.com/pages/news/8225/us-fda-approves-ani-pharmaceuticals-cortrophin-gel-in-prefilled-syringe https://www.market-scope.com/pages/news/8159/repka-plans-to-use-aao-presidency-to-push-for-medicare-payment-reform https://www.market-scope.com/pages/news/8344/four-eylea-biosimilars-get-q-codes-for-billing-payers-in-the-us https://www.market-scope.com/pages/news/8382/four-eylea-biosimilars-get-q-codes-for-billing-payers-in-the-us-1 https://www.market-scope.com/pages/news/8423/us-fda-sets-decision-date-of-oct-21-for-xbrane-s-lucentis-biosimilar-candidate https://www.market-scope.com/pages/news/8306/biocon-reaches-settlement-license-agreement-with-regeneron-to-bring-yesafili-to-market-in-us https://www.market-scope.com/pages/news/8216/formycon-klinge-gain-uk-approval-for-eylea-biosimilar-under-brand-name-ahzantive https://www.market-scope.com/pages/news/8201/appeals-court-upholds-injunctions-blocking-eylea-biosimilars-from-samsung-bioepis-and-formycon https://www.market-scope.com/pages/news/8206/us-fda-accepts-bla-for-aflibercept-biosimilar-candidate-from-alvotech-teva https://www.market-scope.com/pages/news/8114/xbrane-resubmits-bla-to-us-fda-for-ranibizumab-biosimilar https://www.market-scope.com/pages/news/8175/appeals-court-upholds-injunctions-blocking-eylea-biosimilars-from-samsung-biopeis-and-formycon https://www.market-scope.com/pages/news/8145/2024-in-review-flurry-of-eylea-biosimilars-approved-most-blocked-in-us-by-lawsuits https://www.market-scope.com/pages/news/8355/us-fda-extends-luminopia-amblyopia-treatment-clearance-to-children-ages-8-to-12 https://www.market-scope.com/pages/news/8069/amgen-launches-eylea-biosimilar-pavblu-after-court-win-over-regeneron-1